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ABSTRACT 
Kininogens are large molecular mass cysteine proteinase inhibitors belonging 
to class 3 of the cystatin superfamily. They are single-chain proteins composed of an 
N-terminal heavy chain, the bradykinin moiety and a C-terminal light chain held 
together by disulphide bridges. On the bases of their differences in size, structure and 
functions, kininogens of mammalian plasma have been divided into three classes i) 
high molecular weight kininogen (HMWK-MW 88-114 kDa) ii) low molecular 
weight kininogen (LMWK-MW of 50-68 kDa) and iii) T kininogen (MW 68 kDa). 
Important functions of kininogens are the release of vasoactive peptide bradykinin. 
by acting as a substrate for kallikrein, intrinsic blood coagulation, acute phase 
reactions and inhibition of cysteine proteinases. Present study describes the isolation, 
purification and physico-chemical characterization of these inhibitors from sheep 
plasma. 
Kininogens have been characterized from many mammals including human, 
bovine, rat and recently from whale. Kininogens (HMWK, LMWKl and LMWK2) 
were purified to apparent homogeneity from sheep (Av/s Arias) plasma by simple 
three step procedure i.e. ammonium sulphate precipitation, column chromatography 
on Sephacryl-300HR and ion exchange chromatography on DEAE cellulose. Protein 
precipitated between 40-60% ammonium sulphate saturation was dialyzed and 
loaded on S-300HR column. Two protein peaks with papain inhibitory activity were 
obtained. First peak corresponded to HMWK that was found to be homogenous on 
native PAGE. Second peak, which corresponds to LMWK, was heterogeneous and 
was further purified by ion exchange chromatography on DEAE cellulose column. 
Two protein peaks were obtained from ion exchange column corresponding to two 
isoforms LMWKl and LMWK2. The two isoforms were found to be homogenous on 
native PAGE. The yield of HMWK, LMWKl and LMWK2 was about 14.41. 5.63 
and 10.65 respectively. Native PAGE and SDS-PAGE indicated that the inhibitors 
were purified to the extent of homogeneity on the basis of molecular weight and 
charge. HMWK gave a single band on SDS-PAGE with a molecular weight 
corresponding to 280 kDa. Under reducing conditions HMWK gave a single band 
with molecular weight corresponding to 140 kDa indicative of its dimeric nature. 
Purified LMWKl and LMWK2 demonstrated single bands under reducing and non-
reducing conditions, with an apparent molecular weight of 68 kDa. Stokes radii 
( v i ) 
calculated for HMWK, LMWKl and LM\VK2 were found to be 44"a and 35 .3V 
respectively. Purified HMWK, LMWKl and LMWK2 strongly inhibited activities of 
ficin and papain but not of trypsin, chymotrypsin and bromelain. Binding 
stoichiometry of kininogens with papain and ficin gave a molar ratio of 1:2. Ki values 
estimated for HMWK, with papain and ficin was 0.8 nM and 0.6 nM respectiveh'. K, 
values estimated for LMWKl and LMWK2 with papain was 2.40 nM and 2.00 nM 
respectively. As compared to papain, ficin has high association (K-ti) and low-
dissociation rate constants (K.i) with HMWK. The bindings of HMWK, LMWKl 
and LMWK2 to activated papain were accompanied by pronounced changes in 
secondary and tertiary structure. These changes were compatible with perturbations 
of the environment of aromatic residues, arising from local interactions or from a 
conformational change in the proteins involved in complex formation. N- terminal 
analysis of LMWKl and LMWK2 revealed a 20% homology with bovine, porcine 
HMWK and human LMWK. 
Functional state of HMWK on exposure to free radicals was studied by 
incubating HMWK with riboflavin. Riboflavin is known to produce reactive oxygen 
species that mimics biological exposure. Riboflavin sensitized photodynamic 
modifications of high molecular weight kininogen resulted in continuous 
disappearance of the inhibitory activity towards papain and formation of high 
molecular weight adducts with increasing concentration of riboflavin and varying 
time periods of incubation reaching a maximum value of over 85% (loss in activity). 
Aggregates resisted dissociation upon heating at 100°C in 1% SDS. Aggregation and 
photoinactivation of HMWK was promoted by the substitution of H2O for deuterium 
oxide (D2O), which is known to prolong the life span of singlet oxygen and 
suppressed by sodium azide a known singlet oxygen quencher. Mannitol and thiourea 
(hydroxyl radical scavenger) did not protect the antiproteinase activity of HMWK. 
Treatment with reducing agent resulted in decrease of the aggregated products 
suggesting the possible involvement of disulphide linkages in protein crosslinking. 
Tryptophan fluorescence was completely lost and significant production of dityrosine 
was detected by HPLC analysis in photoinactivated HMWK aggregates. Changes in 
the far-UV CD spectrum of HMWK were indicative of loss of secondary structure of 
the inhibitor. Analysis of modifications induced in HMWK by riboflavin revealed 
that the processes proceed via a singlet oxygen mediated pathwa>'. It was concluded 
( v i i ) 
thai the susceptibility of HMWK to oxidation might arise from oxidative 
modifications by reactive oxygen species generated in plasma. 
HMWK from sheep plasma was found to be a homodimer in which a single 
disulphide bond holds the monomers. HMWK on reduction with 0.14 M 2-
mercaptoethanol resulted in complete loss of inhibitory activity towards papain and 
on subsequent air oxidation its activity was almost completely recovered. Presence of 
intermediates during unfolding of HMWK was detected by treating the purified 
protein with varying concentrations of GdnHCl. Changes in inliibitory activity, 
tryptophan fluorescence and circular dichroism in presence of GdnHCl suggested the 
possible intermediates during the course of unfolding. 
( v i i i ) 

1. INTRODUCTION 
GENERAL 
Proteolytic enzymes are of universal occurrence in living systems and perform 
a variety of functions. They have been classified into four different classes namely 
serine, metallo, cysteine and acid proteinases. Serine proteinases have a serine residue 
at their active site. Metalloenzymes require the presence of metal ions for their full 
activity. Cysteine proteinases contain two principal catalytic amino acid residues at 
their active site namely, cysteine and histidine, which are involved in the cleavage of 
peptide bonds connecting the amino acid residues of a protein or peptide substrate. 
Acid proteinases require low pH values for their activity and cleave bonds formed by 
non-polar amino acid residues (Strorer and Mnard, 1994; Stennicki and Salvesen, 
1999). Out of these, cysteine proteinases play very important role in the intracellular 
proteolysis such as catabolism of proteins, antigen processing and presentation and in 
hormone metabolism (Turk et al., 2000; Turk et al., 1997; Turk et al., 2001; Stoka et 
al.. 2001). These proteins are of molecular weight (MW) about 25-35 kDa and are 
synthesized in precursor form in order to prevent unwanted proteolysis. They are 
subjected to co-translational and post-translational modifications that convert them to 
catalytically active mature enzymes (Turk et al., 1996a; Cygler et al., 1996; Turk et 
al.. 2000). 
About 40 different families of cysteine proteinases have so far been 
characterized (Barrett et al., 1998). The first clearly recognized and extensively 
studied cysteine proteinase is papain, isolated from the latex of plant Carica papaya. 
Nearly half of the known families of cysteine proteinases are present only in viruses, 
some occur in bacteria, whereas others exist in eukaroytic organisms (Rawlings and 
Barret, 1990). Current e\ idence suggests that all eleven lysosomal cathepsins known 
to date (B, 11. L. S. C. K. O, 1\ V. X and W) are members of papain family (Kotyza 
and Krepela. 2002). 
Mammalain thiol proteinases are of four different types. 
1 .Cathepsins 2. Legumains 3.Calpains 4.Caspases. 
Cathepsins are found in the lysosomes of cells and are the best characterized 
thiol enzymes. They are evolutionary related to papain and are relatively small 
proteins with the exception of cathepsin C that is an oligomeric enzyme of MW about 
200 kDa. Their concentration is particularly high in spleen (Otto, 1971; McDonald 
and Elis, 1975; Bajkowski and Frankfater, 1975) kidney, liver (Knight, 1980; Quinn 
and Judah, 1978), lung (Singh and Kalnitsky, 1978), brain (Suhar and Marks, 1979) 
and breast (Mort et al., 1984). 
Lcgumains are also present in lysosomes. It is an endopeptidase found to be 
involved in MHC class Il-restricted antigen presentation (Monoury et al., 1998) and in 
the regulation of osteoclasts formation and activity (Choi et al., 1994). 
Calpains and caspascs are cytoplasmic thiol proteinases. Mammalian calpains 
have higher MW of about 110 kDa and participate in many intracellular processes 
such as turnover of cytoskeletal proteins, cell differentiation and regulation of signal 
peptides (Yajima and Kawashima, 2001). The central component of cell apoptosis 
consists of proteolytic systems involving caspases (Nicholson, 1999; Stennnicke and 
Salvesen, 2000). Caspases are the cysteine dependant aspartate specific proteinases. 
Cathepsins are involved in intracellular protein turnover, proteolytic 
degradation and in cleavage of a number of precursor proteins and hormones. They 
play very important role in inflammatory processes and in pathogenesis of diseases 
such as rheumatoid arthritis, pulmonary emphysema, cancer (Koppel et al., 1994) and 
renal failure (Kabanda et al., 1995). Pulmonary emphysema occurs due to proteolysis 
of lung structural proteins by cathepsin G, a proteinase released from 
polymorphonuclear leukocytes (Gabrijeleic et al., 1990). In arthritis and joint 
inflammation there is a breakdown of extracellular proteoglycans. The core protein of 
proteoglycans is susceptible to the action of cathepsin B that produces peptide 
fragments containing one to several polysaccharide chains. Inflammatory reactions of 
whatever origin are accompanied by an increase of lysosomal membrane 
permeability, which provokes the release of lysosomal enzymes, cathepsins. The 
enzyme may come from injured connective tissue or from polymorphonuclear cells. 
In some pathological conditions like ischaemia, hypervitaminosis and on exposure to 
U.V. radiations lysosomal enzymes are released in extracellular space and produce 
extensive damage to the extracellular matrix. 
Regulation of Lysosomal Thiol Proteinase Activitj ' 
Exact mechanism of regulation of thiol proteinase activity is obscure to date, 
however, available evidence on proteolysis suggest that the process is under 
biological control acting al the level of protein biosynthesis or mediated through 
protein inhibitors. At least nine separate well-characterized proteinase inhibitors ha\e 
been recognized in human plasma that shares the capacity to inhibit the activil\ of 
various proteinases (Table 1.0). These inhibitors constitute the third largest group of 
functional proteins in human plasma after albumin and immunoglobulins. Natural 
inhibitors of cysteine proteinases include the members of a cystatin superfamih 
comprising of stefms, cystatins and kininogens. These cystatins constitute a powerful 
regulatory system for endogenous cysteine proteinases, which may otherwise cause 
uncontrolled proteolysis and tissue damage. 
Discoverj' of Cystat in Superfamily 
Protein inhibitors of cysteine proteinases (CPs) in mammalian tissues were 
first reported by Finkelstadt (1957), who reported a heat stable inhibitor of cathcpsin 
B and dipeptidyl peptidase I in rat liver cytosol. Whitaker and coworkers (1968 and 
1973) discovered and partially characterized a protein from chicken egg white that 
inhibits ficin and papain (Fossum and Whitaker, 1968; Sen and Whitaker. 1973). 
Keilova and Tomasek (1974 and 1975) reported that this protein also inhibits 
cathepsin B and dipeptidyl peptidase 1. 
The temi "Cystatin" was originally coined by Barrett (1981) for this protein 
because of its unique property of arresting the activity of cysteine proteinases (CPs). 
Later the name cystatin was given to a superfamily of evolutionary, structurally and 
functionally related proteins involved in the inhibition of cysteine proteinase 
activities. Subsequently cysteine proteinase inhibitors (CPI) from various mammalian 
tissues were isolated and characterized. These inhibitors resembled cysteine 
proteinase inhibitors isolated from chicken egg white, in relative molecular mass and 
physiological properties. Macheildt et al (1983) reported that the sequences ol' 
inhibitors isolated from human liver and chicken cystatin are homologous (Green ct 
al., 1984; Barret, 1985) but differed in lacking cysteine residues and hence, were 
placed in a different family within the cystatin superfamily. 
All cystatins fall into a single superfamily i.e. a group within which all the 
members can be shown to have a statistically significant relation with each other or 
with papain but they do not resemble members of other superfamilies (Dayhoff et al., 
1979a). Cystatin superfamily contains at least three distinct families, the members of 
which have at least half of their amino acid residues in common (Dayhoff et al.. 
1979b), 
TABLE-1.0: P R O T E I N A S E INHIBITORS IN HUMAN PLASMA 
Name Concentra t ion 
in mg/100 ml 
Molecular 
Mass 
(kDa) 
Polypeptide 
Chains 
(No.) 
Reactive 
Sites 
(No.) 
% C a r b o h y d r a t e 
tti-Proteinase 
Inhibitor 290+45 52 1 1 12 
ttp Aiiti-
Chymotrypsiii 49±7 69 1 1 26 
Inter- a -
Trypsin 
Inhibitor 
50 60 1 2 8.4 
a2 Antiplasmin 7±I 70 1 1 11 
Antithrombin 
III 24±2 65 1 1 15 
Ci-inactivator 24+2 65 1 1 15 
tti-Macro-
globulin 260±70 720 4 2 8-11 
pi-
Anticollagenase n.d. 30-33 1 n.d. Traces 
Thiol 
Proteinase 
Inliibitor 
42.5±7 12-175 n.d. n.d. n.d. 
n.d. not determined. 
CLASSIFICATION O F CYSTATIN SUPERFAMILY 
The first international symposium on 'Cysteine Proteinases and their 
hihibitors' in 1985 divided the proteins of cystatin superfamily into three families 1,2 
and 3 (Barrett et al., 1986) on the basis of sequence homology, molecular structure 
and the number of amino acids (Rawlings and Barrett, 1990; Turk et al., 1997; Brzin 
et al., 1984; Turk and Bode. 1991) Fig 1.0. 
Family 1 (Type I Cystatins): Stcfins 
The name stefms has been assigned to the familyl of cystatin superfamily to 
emphasize the structural difference between these proteins and other cystatins. The 
proteins of this family are the smallest among the members of the cystatin 
superfamily lacking disulphide bonds and carbohydrate moieties. Stefins are single 
chain proteins, without signal peptide consisting of about 100 amino acid residues 
(MW 11 kDa). They occur both intracellulary and extracellularly. There are three 
important members of this famil>'. C\'statin A and B isolated from human and stefin C 
from bovine tissues. Cystatin a and [5 arc considered to be simply the rat species 
variants of cystatin A and B. The amino acid sequence of these proteins closely 
resembles each other (Barrett et al.. 1986a). 
Cystatin A 
It is an inhibitor of cathepsin B present in human skin discovered b\ Fraki 
(1976). Later on Jarvinen (1978) studied it as "acid cysteine proteinase inhibitor" 
(ACPI). Brzin et al (1983) purified this inhibitor from blood leucocytes. The amino 
acid sequence of this inhibitor was determined by Machleidt et al (1983). Green et al 
(1984) characterized same type of CPl from human liver and later renamed it as 
cystatin A. 
Cystatin A occurs in multiple isoelectric forms with predominantly acidic pi 
values in the range 4.5-5.0 (.larvinen. 1978: 1 lo|\su-Iiavu el a f . 1983a). Rinnie el al 
(1978) detected cystatin A in extracts of squamous epilliclia from oesophagus. It uas 
also found in dendritic reticulum cells of the lymph nodes (Rinnie et al.. 1983). 
seminal plasma (Minakata and Asano, 1985). saliva, human nails (Tsushima. 1993) 
and in a number of epidermoid carcinomas (Rinnie. 1979. 1980; Rinnie et al.. 1984a) 
as well as in bovine skin (Turk et al.. 1995). Physiological concentration of human 
cystatin A 
Figure 1.0 Diagrammat ic representat ion of the chain s t ruc ture of proteins 
in the cystatin superfamily. 
Type I and II represents stefins and cystatins respectively. Type III indicates 
structures for kininogens, LMW Ivininogen and 1" kininogens. i lMW 
kiuinogens have a longer carboxyterminal extension. The symbol ^ marks 
potential sites for the attachment of carbohydrate side chains. 
Type I 
Type II 
Type III 
• S e g m e n t 1 S e g m e n t 2 S e g m e n t 3 
^ n , , Q j l 
I I I 
was found to be 10-15 ^g/ml in serum, 65-200 jig/g in epidermis of tongue and 8 
^g/g in bone marrow. However its concentration varies from 0.3-8 fig/g in lung, liver 
and spleen (Hopsu-Havu et al., 1983b). 
Cystatin a is assumed to be a species variant of cystatin A found in rats. This 
protein was characterized by Jarvinen (1976) as a specific inhibitor of cysteine 
proteinases from rat skin having MW of 13 kDa. The N-terminal sequence of bovine 
stefm A was identified as a truncated form of bovine cystatin C (Hirado et al.. 1985; 
Turk et al., 1995). Its sequence identity was found to be 86% with human cystatin A. 
Cystatin B 
Cystatin B was detected by Lenney et al (1979) as an inhibitor of cathepsin B 
and H in human tissues. Multiple forms of cystatin B were purified from human 
spleen and liver. Cystatin B is a relatively basic protein with pi values of 6.25 and 
6.35 for the two forms of cystatin B (Green et al.. 1984). Rinnie ct al (1984b) reported 
pi values of 6.5 and 7.5. Human cystatin B forms dimers (Jarvinen and Rinnie. 1982; 
Green et al., 1984; Rinnie et al., 1984b) and the dimeric form is not an acti\e 
inhibitor. 
Cystatin B is ubiquitously distributed in various cells and tissues like epithelial 
cells, lymphocytes (Davies and Barrett, 1984) monocytes (Hopsu-Havu et al., 1984; 
1985b) and to a much lower extent in seminal plasma (Brzin el al., 1982). Jarvinen et 
al (1983) isolated cystatin B from epithelial cells of the oral mucosa. It is also present 
in the nucleus and cytoplasm of differentiated cells (Riccio et al., 2001). fhis cystatin 
is involved in the protection against uncontrolled activity of host lysosomal cysteine 
proteinases (Henskens et al., 1996). Crystal structure of recombinant human cystatin 
B has been elucidated by X-ray crystallography analysis (Stubbs et al.. 1990). 
Cystatin a species variant of cystatin B was isolated from rat li\er 
(I'inkelstadt. 1957; Lenney, 1979) with pi values ranging from 5.04 to 5.6 (Hirado el 
al.. 1981; Kominami et al., 1981). Cystatin p has an almost even distribution in the 
tissues and is more abundant than cystatin a in all tissues except skin. This 
characteristic of cystatin P resembles cystatin B of human variant. 
Stefin C 
Several low MW cystatins have been found in bovine thymus. Although 
kinetically similar they differ in the primary structure and pi values. Stefin C is 
unique among the inhibitors from stefin family, which was found in multiple forms 
(Turk et al., 1993). This property is common to stefins and low MW CPI (Barret et al., 
1986; Brzin et al., 1982; Kopitar et al., 1989). The protein consists of 101 amino acid 
residues and its MW is calculated to be 11.5 kDa. The inhibitor was found to be acidic 
with pi values ranging from 4.5 to 5.6 (Turk et al., 1993). Stefm C exhibits 
considerable sequence homology with inhibitors of this family showing 84.7% 
homology with bovine stefm B, 72.4% with human cystatin B and 47.9% with human 
stefm A. It was identified as the first tryptophan containing stefin at position 20 (Turk 
et al.. 1993). 
Family 2 (Type II): CYSTATIN 
Family 2 cysteine proteinase inhibitors are low MW cystatins. These inhibitors 
are composed of 115-120 amino acid residues having MW of about 13 kDa. These 
contain two disulphide bonds and lack carbohydrate content. They are synthesized 
with the signal peptide and found at a relatively high concentration in secretions like 
chicken egg white, seminal plasma, and saliva. They originate in cells and may also 
function intracellulary. The known members of this femily are chicken cystatin. 
human cystatin C, D, S, SN, SA. E, F and M. Measurements of the concentration of 
cystatin in human biological fiuids reveals that all such fiuids contain inhibitors but 
the total content of different inhibitors vary markedly. Cystatins are found both in 
cells and tissues (Lofberg et al., 1983). The general pattern seems that secretions 
contain the highest concentration of family 2 cystatins (Abrahamson, 1994). The best-
known represenlati\ e of this class of cystatins are human cystatin C and chicken 
cystatin. I he pi \ alucs range from 4.4 to 9.3. 
Cystalin ( 
Cystatin C was found in urine from patients with renal failure (Butler and 
Flynn, 1961) ascitic and pleural fiuids (Hochwald and Thornbecke, 1962). Later 
cystatin C was also detected in saliva, normal serum (Cejka and Fleischmann, 1973) 
and in seminal plasma (Colle et al.. 1976). Lofterg and Grubb (1979) determined 
cystatin C concentrations as 5.8 |.ig/ml in cerebrospinal fiuid. 1.8 mg/ml in sali\a and 
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0.095 (.ig/ml in normal urine. 21 i^ig/ml in urine from patients with renal tubular 
disorders and 1.1 [,ig/ml in normal plasma. Seminal plasma contains 50 (.rg/ml i.e. 36 
fold higher coneentration of inhibitor than in normal blood plasma (Grubb el al., 
1983). The high level of cystatin C in the cerebrospinal fluid compared with blood 
plasma suggests the production of this cystatin in the central nervous system (I.oiberg 
and Grubb, 1979). The protein is able to cross blood brain barrier to the vascular 
space thereby rapidly filtered in the glomeruli and gets catabolised in the renal tubular 
cells. Isoelectric point of cystatin C was found in the range of 8.0 to 9.0 (Cejka and 
Fleischmann, 1973; Laurenzi and Link, 1978; Brzin et al., 1984). 
One of the best-described examples of cystatin C is chicken cystatin. Chicken 
cystatin was first isolated from chicken egg white by Possum and Whitaker (1968) 
and later by Sen and Whitaker (1973) as low MW tight binding cysteine proteinase 
inhibitor of ficin, papain, cathepsin B and cathepsin C (Keilo\'a and Tomasek. 1974; 
1975). Chicken cystatin has also been detected in the serum of both male and female 
chicken (Anastasi et al., 1983) and in chicken muscle cell (Wood et al.. 1985). It is 
present at a concentration of 80 )ig/ml in egg white and at about 1 ).ig/ml in the serum 
(Anastasi et al., 1983). A MW of about 13 kDa has been determined from the amino 
acid composition (Lindahl et al.. 1988). 
Cystatin D 
Cystatin D is a relatively neutral protein with pi values in the range 6.8 lo 7.8 
(Freije et al., 1991). This inhibitor consists of 122 amino acid residues having a MW 
of 13.8 kDa. The deduced amino acid sequence includes putative signal peptide and 
has 51-55% homology with either cystatin C or secretory gland cystatins S. SA and 
SN. It is expressed in parotid glands, saliva and tears (Balbin et al.. 1994). 
Cystatin S 
Human saliva contains several low MW acidic proteins, which also include 
cysteine proteinase inhibitors (Isemura et al., 1984b: Minakata and Asano. 1984). 
Isemura et al (1984a) first purified and sequenced 'cystatin S". It was found to ha\c 
54% and 41% sequence homology with cystatin C and chicken cystatin. respectively 
(Isemura, 1984 a, b). This inhibitor has also been isolated from human submaxillar}', 
submandibular and sublingual glands and found to be present in the serous cells of 
parotid and submaxillary glands. The protein has also been found in the tears, scrum, 
urine, bile, pancreas and bronchus (Isemura et al.. 1986). 
Cystatin E 
Ni et al (1997) found this type of cystatin by expression of the amniotic and 
fetal skin epithelial cell cDNA libraries. The mature protein is a polypeptide of 121 
amino acid residues and has 28-residue signal peptide having a MW of 15 kDa. The 
inhibitor has unusual characteristic of being a glycoprotein carrying an N-linked 
oligosaccharide at Asn 108.Cystatin E has been detected in a variety of specialized 
tissues and organs. High concentration of this inhibitor has been found in uterus and 
liver, low cystatin E amounts are found in brain, testis and kidney. Lower but 
significant amounts are found in placenta, pancreas, heart, spleen, small intestine and 
peripheral blood leucocytes. The inhibitor serves a protective role during fetal 
development (Ni et al., 1997). 
Cystatin F 
Another cystatin described as human member of the cystatin supcrfamily has 
been identified as cystatin F by Ni et al (1998). Its whole sequence contains a signal 
peptide. The mature protein of 126 amino acid residues contains two disulphide 
bonds, which resembles family 2 cystatins. Unlike other members, cystatin F has two 
additional cysteine residues indicating the presence of an extra disulphide bridge that 
stabilizes the N-terminal region of the molecule. Cysatin F has a MW of 14.5 kDa as 
determined by sequence analysis.The distribution pattern of cystatin F is very 
different from that of cystatin C and E. Blood contains low levels of this inhibitor. 
The highest concentration is present in the spleen and peripheral blood leucocytes, 
moderate levels in thymus and small intestine. Cystatin F is found mostly in the 
immune cells. 
Cystatin M 
Cystatin M was discovered in the primary tumour cell line. Its molecular mass 
is approximately 14.3 kDa and pi value is 7.8. It contains a single disulphide bond 
(Sotriopoulo et al., 1997). An N-glycosylated form of cystatin M of MW 20-22 kDa 
was co-immunoprecipated and accounted for about 30-40% of total cystatin M . Both 
forms of native cystatin M occur intracellulary. Normal mammary epithelial cells and 
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a variety of human tissues express cystatin M. High levels of cystatin M are present in 
placenta, lung, skeletal muscle, kidney and pancreas. 
KIN I NO GENS 
The most complex cystatin molecules of the cystatin superfamily are those of 
the Type 3, the kininogens. Kininogens have come a long way since their prediction 
as kinin precursors by Werle (1937). Jarvinen (1976) detected a cysteine proteinase 
inhibitor of MW 70 kDa in rat skin and later a similar protein was partially purified 
from human serum, with a2-electrophoretic mobility that was named as a2-thiol 
proteinase inhibitor (a2TPI) (Sasaki et al., 1977). Ryley (1979) purified the inhibitor 
migrating in both ai and 02 positions. The two immunologically identical forms had 
different MW values (170 kDa and 90 kDa). Three forms of the inhibitor differing in 
MW and pi values were isolated and the term a 1-thiol proteinase inhibitor (aiTPI) 
was gi\en for the highest MW form, which had the highest anodal mobility and 
retaining a2-TPl| and a2-TPl2 for other forms. Sasaki el al (1981) and Gounaris 
(1984) purified a cysteine proteinase inhibitor (a-CPI) by affinity chromatography on 
Cm papain sepharose and separated the forms by ion-exchange chromatography. 
Confirming the identity of the kininogens with the forms of a-cysteine proteinase 
inhibitor. Sueyoshi et al (1985a) and Miiller-Esterl et al (1985a) showed that the 
kininogens are potent inhibitors of cysteine proteinases. 
Functions of Kininogens 
Kininogens are known to serve a variety of physiologically important 
functions, ' fhey are involved in the early events of intrinsic blood coagulation. The 
intact kininogen molecule without prior liberation of kinin can execute this function. 
This activity was revealed by detailed study of kininogen deficient individuals 
(Colman et al.. 1975). Kininogen are the natural substrates for kallikrein like 
proteases. Proteolytic cleavage ol two susceptible peptide bonds in the interior of a 
kininogen molecule releases the effecuve peptide and generates a kinin free kininogen 
with an amino terminal heavy chain and a carbo\ \T terminal light chain. These two 
chains are interconnected via a smgle disulphide bridge, funct ions affected via kinins 
released by the action of kallikriens arc i) the smooth muscle contraction ii) induction 
of hypotension and iii) increase of vascular permeability. Depending on the kind of 
kininogen and the cleavage specificity of the proteinase applied, four types of kinins 
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can be generated. The nonapeplide bradykinin (Arg-Pro-Pro-Gly-Phc-Ser-Pro-Phc-
Arg) the decapeptide kallidin (ahas Lys-bradykinin) Lys-Arg-Pro-Pro-Gly-Phe-Ser-
Pro-Phe-Arg and undecapeptide such as Mct-L.ys-bradykinin or lle-Scr-brad)kinin 
(also named T-kinin). The kinins share a common consensus sequence of nine amino 
acids at their carboxy-termini (Arg-l'ro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) but differ by 
size and structure of their amino termini (Kato et ah, 1981). Two other novel 
functions of kininogen, unrelated to kinin release were also discovered. First 
kininogens were demonstrated to be potent inhibitors of cysteine proteinases such as 
papain, calpain and cathepsins (Ohkubo et a!.. 1984; Sueyoshi et al., 1985b; Miiller-
Esterl, 1985b). Second kininogen was shown to be the major acute phase reactant in 
rat (Kato et al., 1985a; Anderson and Meath. 1985; Cole et al., 1985). The 
biosynthesis of this type of kininogen is dramatically increased under inflammatory 
conditions. Kininogens are thus multipurpose proteins, which are involved in kinin 
generating pathway, blood coagulation ca.scade. the inhibitor defense system and the 
acute phase response. Three types of kininogens have been found in mammals 
differing in size, structure and functions. The largest kinin precursor commonly 
referred to as high molecular weight kininogen (HMWK) has a MW of 88-120 kDa. 
depending on its species origin (Kato et al.. 1981). The smaller kininogen, a low 
molecular weight kininogen (LMWK) with a MW of 50-70 kDa is also found 
throughout the mammalian lineage. The third t)pe. T kininogen of MW 68 kDa seems 
to be unique to rats (Okamato and Greenbaum. 1983). 
H I G H M O L E C U L A R W E I G H T KININOGEN 
Properties 
High molecular weight kininogen (HMWK) having a molecular weight range 
of 88-120 kDa is composed of 571 to 999 amino acid residues. HMWK consists of 
heavy chain (MW 48-62 kDa, 337-560 amino acid residuesl. histidine and ehcinc 
rich fragment 1.2 (MW 14.5-16 kDa, 110 amino acid residues) and light chain (\4W 
16-43 kDa, 123-399 amino acid residues) (Iwanaga et al.. 1979: Kato et al.. 1981; 
Sueyoshi et al., 1987). Human HMWK has an isoelectric point of 4.45-4.65 
(Gjonnaess. 1972) and a plasma concentration of 70-90 [.ig/ml (Bouma et al.. 1980; 
Proud et al., 1980 and Schmaier et al., 1983). Histidine and glycine rich regions arc 
responsible for binding to negatively charged surlace of glass (Retzois et al.. 1987). 
Putative in vivo anionic surfaces are the altered endothelial cell surfacc or the sub 
endothelial matrix exposed in a damaged vessel. It has been found that eritical amino 
acids within the histidine and glycine rich region that are responsible for binding to a 
negatively charged surface and for the interaction with Zn^^ ions are residues from 
459-474 (DeLa Cadena and Colman, 1991). 
HMWK light chain, which possesses the coagulant activity, depends on the 
activity of cleaved HMWK to bind to anionic surface and to associate with the 
zymogens prekallikrein, via residues 556-595, or factor XI, via residues 556-613 ( fait 
and Fujikawa, 1987). About half of the HMWK circulates in plasma as a complex 
with factor XI and prekallikrein (Mandle et al.. 1976; Scott and Colman. 1980). 
HMWK is involved in the contact system of blood coagulation by serving as a 
cofactor for several enzymatic reactions in the contact phase. Factor XII binds to 
negatively charged surfaces in the absence of other proteins, but HMWK is necessary 
for efficient binding of both prekallikrein (PK) and factor XI (Silverberg et al.. 1980). 
Bound factor XII can autocatalytically activate factor XII to Xlla, but this is a slow 
reaction. On the surface, prekallikrein and factor XII are involved in rapid reciprocal 
activation reaction (Fujikawa et al., 1980). Such that factor XIa activates prekallikrein 
(bound to HMWK) to kallikrein, which in turn activates factor Xll to factor Xlla. 
Factor Xlla then converts factor XI (bound to HMWK) to factor XIa. which in turn 
activates factor IX to IXa. Thus FIMWK acts as a bridging molccule between a cell 
surface (such as neutrophils or endothelial cells) and factor XI or prekallikrein to 
enhance their local concentration and allow more rapid cleavage of these zymogens 
by factor Xlla. HMWK contains a large amount of 0-linked carbohydrate in its light 
chain; there is also N-Iinked carbohydrate in the heavy chain. Many of the 
oligosaccharide chains are located in a stretch of the light chain beyond the highl\' 
positively charged region, closer to the carboxyl-terminal end of the molecule but 
these are not required for coagulent activity (Kunapali et al., 1992) 
Interaction of Kininogen With Cells 
HMWK can bind to platelets, neutrophils and endothelial cells and the 
presence of Zn^^ ions is an absolute requirement in all cases, ' fwo sites on kininogen 
were found to be responsible for binding to platelets and neutrophils HMWK light 
chain interacts with blood and vascular cells (Van Iwaardcn et al., 1988; Schmaier et 
al., 1988; Gustafson et al., 1986; Greengard et al.. 1986; Meloni and Schmaier, 1991). 
However LMWK, which lack 85% of the HMWK light chain also can bind to 
platelets, therefore the rudimentary LMWK light chain was not responsible. A 
monoclonal antibody directed against the heavy chain of kininogen prevented the 
binding of HMWK to neutrophils (Sueyoshi et al., 1985b) suggesting that the heavy 
chain is another site for binding to neutrophils and platelets (Watchfogel et al., 1990). 
On endothelial cells, kininogen can serve as a source of kinin that stimulates 
prostacyclin synthesis (Cole et al., 1985). On neutrophils, HMWK acts as an acquired 
receptor for the binding of kallikrein, which mediates neutrophil aggregation and 
degranulation (Hirado et al., 1985) On platelets, HMWK acts as a binding site for 
factor XI, and both kininogens inhibit thrombin binding. A novel kininogen-platelet 
interaction has been described between HMWK and platelet thrombospondin by DeLa 
Cadena et al (1990). Interaction between HMWK and platelet thrombospondin 
involves exposure of thrombospondin on the surface of thrombin-stimulated platelets 
that increases the binding of HMWK four to five fold. Unlike the Ca'^ dependent 
thrombospondin-HMWK interaction with domain 3 of the heavy chain, HMWK light 
chain after digestion by plasma kallikrein, can interact with thrombospondin in a 
Ca^^independent manner. 
Binding of H M W K with Ferr i t in Binding Protein 
HMWK has been identified as ferritin binding protein (Torti and Torti, 1998). 
Ferritin is an iron binding protein that is found in most human tissues and in human 
serum. It is a 24-subunit protein composed of two chains termed H and L (Theil. 
1987; Harrison et al., 1991; Harrison and Arosio, 1996). Ferritin levels are elevated 
during acute and chronic inflammation and in many cancers. Ferritin binds to the light 
chain of HMWK thus targeting the light chain-dependent functions, such as binding 
to kallikrein or cell surfaces (Hasan et al.. 1995). Torti and Torti (1998) proposed that 
the interaction between HMWK and ferritin might take place at localized sites, for 
example at cell surfaces, sites at which HMWK and ferritin both individually bind 
(Farigion ot al.. 1988; Takami et al., 1986; Adams et al., 1988; Osterloh and Aisen, 
1989; Moss et al., 1992;Van Iwaarden et al.. 1988; Meloni et al., 1992; Henderson et 
al.. 1994). Such a mechanism leads to a paracrine like effects similar to that exhibited 
by certain cytokines (e.g. interleukin 1 and interleukin 6) hormones and growlh 
factors. 
L O W M O L E C U L A R W E I G H T KININOGEN 
Low molecular weight kininogen (LMWK) has an isoelectric point of 4.45-4,9 
(Kato et al., 1981) and plasma concentration of approximately 160 [ag/ml in humans 
(Muller-Esterl, 1982a). It has a MW of 50-70 kDa. The heavy chain of LMWK is 
identical to heavy chain of HN4WK and is responsible for the inhibition of enzymes 
that contain cysteine residue at their active sites, such as the Ca^^ activated cysteine 
proteinases calpains, papain, cathepsin L and to lesser degree, cathepsin H (Sueyoshi 
et al., 1985b). The heavy chain of LMWK consists of three tandemly repeated 
domains I, II and III (Salvesen et al., 1986; Kellerman et al., 1986). Domain II and III 
are more closely related and contain the pentapeptide Gln-Val-Val-Ala-Gly a 
sequence motif well conserved throughout the superfamily of mammalian cysteine 
proteinase inhibitors, including cystatins and stefins. Calpain is inhibited by domain 
II, whereas papain and cathepsin L arc inhibited effectively by domain II and HI 
together. Inhibition of calpain by IIMWK and LMWK is achieved by reversible and 
tight binding, with a Ki of 0.5 nM and 2 nM respectively (Bradford et al.. 1990). 
Although domain I doesn't contain a cysteine inhibitory activity, it docs contain a 
low-affinity Ca'^binding site with a dissociation constant of about 330 (.iM 
(Higashiyama, 1987). Ca^^ dependent interaction was found between the adhesive 
protein thrombospondin and the heavy chain of HMWK and l.MWK. The region on 
the heavy chain that interacts with thrombspondin is locatcd in domain III (residues 
265-272). Conformational changes in LMWK and HMWK heavy chain were induced 
by metal ions such as Ca^ "^  and Mg^ "* dctccted hy circular dichroism (Higashiyama. 
1987). The conformational change in domain 1 of the heavy chain of HMWK and 
LMWK that occurs in the presence of Ca"' ions e.xposes a region on domain 111 tliat is 
capable of binding to thrombospondin (DeLa Cadena and Colman. 1991). 
DOMAIN S T R U C T U R E O F KININOGENS 
The various types of kininogens have the same basic structure, a hca\ > chain 
of about 50-60 kDa, preformed at the amino terminus, the kinin segment in the core 
part of the molecules, and the preformed light chain of variable length at the carboxy-
terminus (Kitamura et al., 1983; Takagaki et al., 1985; Nawa et al., 1983; Lottspcich 
et al.. 1985; Kcllermann et al., 1986). The primary structure of the hea\y chain 
portion, the kinin section and a consecutive segment of 12 amino acids are identical in 
HMWK and LMWK but the structure of their light chains diverge considerabh. 
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Human HMWK has a large light chain of 40-45 kDa (Sugo et al., 1980). LMWK 
molecule has a rudimentary light chain of only 4-5 kDa lacking the segments critical 
for contact activation or proenzyme binding (Kato et al., 1981; Lottspeich et al., 1985; 
Miiller-Esterl et al., 1985b). The structure of T-kininogen closely resembles that of 
LMWK in its heavy and light chain portion (Kato et al., 1985a; Anderson and Heath, 
1985: Cole et al., 1985) but differs at the amino terminal flanking region of the kinin 
segment. LMWK contain the canonical bradykinin sequence preceded by the 
dipeptides Met-Lys or Met-Arg (Kato et al., 1985b), while T-kininogen harbors an 
Ile-Ser-bradykinin sequence preceded by the dipeptide Met-Met (Kato et al., 1985a). 
LMWK sequences are susceptible to proteolytic cleavage by the kallikreins whereas 
T-kininogen sequence is cleaved by trypsin or cathepsin D that releases the effector 
peptide T-kinin from T-kininogen (Okamoto and Greenbaum, 1983). 
A model for the molecular architecture of the kininogens, which reflects the 
functional diversity of the protein, emerged after dissecting the kininogens into single 
functional units by limited proteolysis (Kato et al., 1981; Salvesen et al.. 1986). 
According to this model the kininogen possess five (LMWK, T- kininogen) or six 
(HMWK) domains Fig. (1.1). Three domains form the heavy chain portion of the 
kininogen encoded by a triplet set of exons. Two of the three heavy chain domains of 
the kininogen is encoded by a triplet set of exons and have reactive sites for 
proteinase inhibition (Salvesen et al., 1986). The kinin domain follows this triad of 
heavy chain domains. Distal from the kinin segment, the HMWK light chain exposes 
another pair of domains, one of them encompassing recipient structure for 
prekallikreins and factor XL The light chains of LMWK and T-kininogen are formed 
by a single domain each. This model implies the functional and structural versatility 
of the three types of kininogen brought about by the elective combination of limited 
number of domains carrying and executing the diverse functions of the proteins. 
A G G R E G A T I O N O F KININOGKNS 
An interesting feature of purified human kininogens is their tendency to form 
oligomers (Table 1.1). High molecular weight kininogen forms dimers, tctramers and 
hexamers. Gel filtration experiments with kininogen fragments demonstrated that the 
isolated heavy chain from HMWK is eluted with an apparent MW of 130 kDa i.e. it 
Figure 1.1 Schematic d iagram of the s t ruc ture of high molecuhir weight 
kininogen 
The heavy chain of HMWK (identical to that of LMWK) comprises domains 1,2 
and 3 (Dl , D2 and D3). The three sites where plasma kallikrein cleaves MMWK. 
arc arrowed. The circles wit +ve signs on 1)5 represent the histidine and glycine 
regions of the light chain of HMWK that is responsible for interaction with Zn'^ 
ions and artificial negatively charged surfaces. The regions that bind factor XI 
and prekall ikrein are indicated on D6. 
17 
HOOC 
/ prekallirein 
factor 
X I - -
556 
=bradyk in in 
2nd cleavage 
3rd cleavage 
TABLE-1.1: M O L E C U L A R W E I G H T S O F K I N I N O G E N O L I G O M E R S AS 
D E T E R M I N E D BY G R A D I E N T P O L Y A C R Y L A M I D E G E L E L E C T R O -
P H O R E S I S IN T H E ABSENCE OF DISSOCIATING AGENTS 
Oligomer L M W K ' H M W K 
Monomer 68,000 140,000 
Dimer 136,000 350,000 
Tetramer 272,000 540,000 
Hexamer 408,000 n.d. 
Octamer 544,000 n.d. 
Decamer 680.000 n.d. 
n.d .= not d e t e r m i n e d . 
" C a l c u l a t e d f r o m M W of 6 8 , 0 0 0 fo r low m o l e c u l a r w e i g h t k i n i n o g e n d e t e r m i n e d by S D S - P A G E 
( 4 - 3 0 % ) . 
dimerizes whereas the corresponding light chain does not. Hence oligomcrization of 
human kininogen is mediated by the heavy chain common to both types of i^ininogen 
(Muller-Esterl et al., 1982b). 
Occurrence of kininogen oligomers in plasma seems unlikely as; HMWK is 
known to form binary complexes with blood clotting factors (Bouma et al.. 1982). 
Removal of these associated proteins during purification procedure may unshield the 
corresponding binding sites of HMWK purified protein. Appearance of multiple 
forms of human kininogen is most probably due to kininogen oligomers rather than to 
kininogen precursor molecules (Pierce and Guimaraes, 1976). 
S T R U C T U R E O F K I N I N O G E N S 
Amino acid Composit ion 
Amino acid composition of HMWK from bovine and horse are very similar, 
but both differ from human HMWK (Table 1.2). The values had been calculated by 
assuming that the molecular weight of the pohpeptide moiety in human HMWK is 
113 kDa(Kato et al., 1981). 
Kitamura et al (1985) and Salvesen et al (1986) had noted that, three cystatin 
like sequences are present; although the first one lacks the Gln-Val-Val-Ala-Gly 
sequence, the arrangement of cysteine residues is clearly conserved. 
Secondarj ' S t ruc ture 
Analysis of the amino acid sequences provide evidence for the distribution of 
hydrophilic and hydrophobic residues. Predicted hydrophilic regions are considered to 
be on the surface of the protein whereas hydrophobic regions are internal, fhe 
hydropathy profile of human HMWK showed that the heav)' chain has an o\erall 
hydrophilic structure with only a few hydrophobic regions (Fig 1.2). The molecule 
has a low degree of helical contcnt especially in its C terminal region. The large 
number of turns suggested that the heavy chain has a very flexible structure 
(Kellermanet al., 1986). 
Compute r Genera ted Model of H M W K Domain II, Domain III, and Cystatin. 
Structural information for egg white cystatin determined from the 
crystallographic X-ray diffraction patterns (Bode et al.. 1988) yielded coordinates for 
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TABLE-1.2: AMINO ACID COMPOSITION OF PLASMA THIOL PROTEINASE 
INHIBITOR. 
Data calculated from published amino acid sequences for HMVVK and LMWK 
HMVV kin inogen LM W Kinino 
I 
4en 
Amino Bovine" Horse'' Human" Bovine'' H u m a n ' Rabbit^ 
acid 
residues 
No. of 
Amino 
acids 
Mole 
% 
No. of 
Amino 
acids 
Mole 
% 
No. of 
Amino 
acids 
Mole No. of 
Amino 
acids 
Mole % Mole 
Asp 63 10.8 64 11.0 116 11.6 37 9.8 10.8 
Thr 41 7.1 39 6.7 79 7.8 24 8.4 7.7 
Ser 49 8.5 28 4.8 74 7.4 28 8.7 6.3 
Glu 64 11.1 74 12.7 137 13.7 46 14.4 10.5 
Pro 39 6.6 53 9.1 64 6.4 26 5.6 6.3 
Gly 39 6.7 48 8.3 72 7.2 20 6.4 7.7 
Ala 31 5.4 31 5.3 46 4.6 26 7.0 7.4 
'/2 Cys 20 3.5 16 2.8 2.2 16 2.8 4.3 
Va! 38 6.6 31 5.3 45 4.5 30 6.1 5.4 
Met 8 1.4 5 0.9 9 0.9 s 0.7 6.9 
lie 22 3.8 25 4.3 48 4.8 ' l Y - - 4.6 i 
Leu 36 6.2 38 6.5 52 5.2 23 5.8 6.8 
i 
Tyr 19 3.3 13 2.2 31 ^3.1 ' 13 3.6 r ' 2 T " " 
Phe 20 3.5 19 J .J 39 3.9 14 4.3 4.3 
His 28 4.9 32 5.5 48 4.8 9 3.0 
Lys 43 7.3 39 6.7 73 7.3 26 6.8 i 
Arg 13 2.3 22 3.8 32 3.2 1 1 3.7 • " 1 8 ^ ^ 
Trp 8 1.3 4 0.7 12 1.2 4 
Tota l 
re s idues 
581 581 999 315 
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•'Komiya e ta l (1974) 
''Sugo e ta l (1981) 
'Nakayasu and Nagasawa (1979) 
''Nagasawa et al (1979) 
l^lagasawa and Nakayasu (1979) 
'Egorova et al (1976) 
"Sakamoto and Nishikaze (1979) 
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Figure 1.2 Secondary s t ruc ture prediction of the heavy chain of human 
H M W K 
a-helix is represented by a wavy line (positions 30-45). (] sheet by a zigzag 
(positions 19-25) P turns by a zigzag around a bend (alter positions 50), 
random coil by undulations (positions 100-125) and carbohydrate side chains 
by a black diamond (position 150). Numbers denote the relative positions of 
the amino acid residues in the complete kininogcn sequence. 
2 1 
COOH 
ihe three dimensional assembly of eaeh linear amino acid sequence. These 
determinations provided a reasonably accurate prediction of the backbone structure 
for the cystatin family of proteins on which other closely related amino acid 
sequences of D II and D III of human HMWK were modeled (Fig 1.3). The three 
dimensional computer models showed that the three regions chosen from the amino 
acid comparison, which are separated by more than 30 amino acid sequences in the 
linear sequence, are arrayed in a continuous hydrated surface hinged on the central 
QVVAG sequence. The model for domain II has obvious conformational variations 
when compared with domain III. 
D III more closely resembles the analogous surface formed in the cystatin 
model (Fig 1.3). Model generated for HMWK D 111 has a pocket or cleft which is 
formed between the 185-198 and 229-248 peptide sequences. The homologous 
regions in the model of cystatin and D III contain a proline, which imparts a hairpin 
turn in these structures that is absent in the D 11 structural model (Bradford et al., 
1993). 
INHIBITION O F P R O T E I N A S E S BY KININOCENS 
All the enzymes known to be inhibited by the cystatins are proteinases with 
cysteine at active sites. No example is available for serine, aspartic or metallo-
proteinases or non-proteolytic enzymes being inhibited by cystatins. The available 
data indicates that all cystatins inhibit cysteine proteinases of papain superfamily 
including papain, chymopapain, papaya proteinase III. ficin. actinidin and the 
lysosomal cysteine proteinase, eathepsin B. 11 and L. 
HMWK purified from human were found to be tight binding, reversible 
competitive inhibitors with the substrate with no detectable cleavage of the reactive 
domains. HMWK inhibits papain, eathepsin H and I, with K, values 34 pM. 1.1 nM 
and 62 pM respectively. Inhibition of eathepsin B was found to he much weaker with 
Kj value 0.35 pM. Dipeptidyl peptidase I was also weakly inhibited with K., (approx.) 
0.13 [.iM (Gounaris et al., 1984). HMWK do not inhibit trypsin. ch>motrx psin and 
bromelain. 
Inhibitory activities of bovine kininogen and their derivatives. HMWK kinin 
free protein, HMWK kinin and fragment 1.2 free proteins and LMWK kinin free 
protein showed strong inhibitory activity for thiol proteinases (Sueyoshi et al., 1985b). 
Figure 1.3 C o m p u t e r generated model of H M W K domain 2, domain 3 
and eystatin 
The computer representation of domain 2 and 3 region tiiat inhibits papain 
encompasses the first 12 residues of the NI I2 terminus (peptide 146-157). The 
location for the QVV region in D 2 peptide (185-198) is indicated in Hght bhie 
and the NAY region in D 2 peptide (229-248) is depicted in dark blue. These 
two peptide areas form a contiguous hydrated surface in the three-dimensional 
model for protein interactions. Homologous regions are colored similarly as 
eystatin and D 3. The rest of the molecules are indicated in red. 
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S-alkylated heavy chain prepared from bovine HMWK Icinin free protein did not 
show any inhibitory activity attributed to a conformational change induced during the 
reduction and S- allcylation procedure (Tablel.3). 
INHIBITION O F a - T H R O M B I N 
Kininogens inhibit a-thrombin activation of platelets by being a non-
competitive inhibitor of a-thrombin specific binding site on platelets (Meloni and 
Schmaier, 1991). Vu et al., (1991) reported that the binding of a-thrombin to its 
receptor results in the receptors cleavage at the amino terminus. The new amino 
terminus then functions as the agonist for platelets activation. Kininogens inhibit 
thrombin induced platelet activation by simply blocking a-thrombin binding and not 
inhibiting either the cleavage of the thrombin receptor or the ability of the new amino 
terminus of the receptor to activate platelets. Domain III inhibits a-thrombin platelet 
binding and activation similar to HMWK and LMWK. Domain 111 is a less efficient 
inhibitor of a- thrombin induced platelet secretion than HMWK. The IC50 for HMWK 
inhibition of secretion has been reported to be between 30 and 50 nM, but for D 111 it 
is between 125 and 200 nM (Jiang et al., 1992). 
M E C H A N I S M O F I N T E R A C T I O N O F KININOGENS W I T H PROTEINASES 
The mechanism of inhibition of papain by chicken egg white cystatin has been 
extensively studied. Bode et al (1988) proposed the interaction of cystatin with 
cysteine proteinase based on X-ray crystallography of chicken cystatin and 
subsequent studies based on computer docking experiments. Three parts of the 
inhibitor are in close contact with the active site cleft of papain, i) the amino terminus, 
ii) QVVAG sequence (Barrett et al., 1986; Barrett, 1987) iii) and a second hairpin 
loop (residues 102-107) containing the conserved Trp 104. The major contribution is 
from the hairpin loop containing the QVVAG sequence (Turk, 1985; Ohkubo et al.. 
1984; Bode et al., 1988). According to the model the N-terminal segment of cystatin 
which is more flexible, bridges over the active site Cys 25 residue of papain without 
completely burying it and additionally the side chain of Leu 8 binds to the S2 subsite 
of papain which determines the substrate specificity of papain (Drenth et al., 1976; 
Asboth et al., 1988). The side chain groups of QLVSG segment makes the most 
intimate contacts with putative S| subsite of papain, ( f i g 1.4). 'fhis explains the 
2 4 
TABLE 1.3: *Ki VALUES FOR THE INHIBITION OF VARIOUS THIOL 
PROTEINASES BY HMWK, LMWK AND THEIR DERIVATIVES 
Source Cathepsin B Cathepsin L Cathepsin H Papain 
Bovine 
HMWK 12 0.7 15 0.07 
HMWK kinin free protein 1.2 0.4 7.8 0.04 
HMWK kinin and fragment 
1.2 free protein 2.0 1.8 12 0.01 
LMWK 23 1.8 44 0.05 
LMWK kinin-free protein 11 1.7 9.21 0.02 
Rat 
HMWK 45 1.2 >2000 0.11 
T-kininogen 170 2.8 470 0.19 
Human 
HMWK kinin-free protein 170 0.2 1.9 0.02 
"K, va lues are e x p r e s s e d as n M . 
2 5 
Figure 1.4 Schcnie of the proposed model for the interaetion of ehieUeii 
eystatin with papain 
Interaction of chicken cystatin witli papain has been illustrated 
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presence of Gly 9 in close vicinity of but not in direct contact with Cys 25 of papain. 
Removal of Leu 7 and Leu 8 leads to an approximately 5000 fold lower affinity ibr 
papain. 
Nycander and Bjork (1990) emphasized the role of Trp 104 in ihc inhibition of 
cysteine proteinases. According to their model, Trp 104 of cystatin interacts primarily 
with two-tryptophan side chains in the active site cleft of papain. Trp 177 and Trp 
181, in such a manner that the indole ring of Trp 104 stacks on the side chain of Trp 
177 and lies edge on the indole ring of Trp 181. 
A two-step mechanism of inhibition of the lysosomal cysteine proteinase, 
cathepsin B by its endogenous inliibitors, cystatin C was observed by Nycander et al 
(1998). An initial weak interaction in which N-terminal of the inhibitor binds to the 
proteinase is followed by a conformational change. Subsequently, the inhibitor 
bringing about conformational change displaces the occluding loop of the proteinase 
that partially obscures the active site. The presence of the occluding loop of cathepsin 
B renders it much less susceptible to inhibition by cystatins than other proteinases. 
Kininogens can bind with papain inactivated by L-3-carboxy-2.3-trans-
epoxypropionylleucylamido (4-guanidino) butane (L-64 the synthetic inhibitor) or 
iodoacetic acid (Sueyoshi et al., 1988). E-64 shows strong inhibition specifically lor 
cysteine proteinases. Epoxysuecinyl group of E-64 irreversibly binds with an active 
thiol group of cysteine proteinases to form a thioether linkage (Towatari ct al.. 1978; 
Towatari et al., 1979; Hashida et al., 1980). Therefore active site thiol group is not 
required for the interaction of kininogen with cysteine protienase. It has been 
established that no disulphide bond is formed between the active site of c\ steine 
proteinase and the inhibitor because complexes dissociates when denatured without 
reduction (Nicklin and Barrett, 1984; Gounaris et al., 1984) and carboxymethylatu)n 
of enzyme and inhibitor does not prevent complex formation (Anassatasi et al.. 19K3). 
The interaction between the kininogen and S2 site of papain is hydrophobic because 
papain has several hydrophobic amino acids near the active site cleft at the S2 site 
(Drenth et al., 1976). Kininogen also have a very hydrophobic region in domain 111 
near the conserved sequence QVVAG that is involved in binding to cysteine 
proteinases. 
EVOLLITION O F M A M M A L I A N KININOGENS 
The e lucidal ion of the structural organiza t ion of the l iuman kininogcn gene 
revealed the re la t ionship be tween the protein doma ins ol~ k in inogen and the exon 
intron a r rangement s o f their coding gene. It was found that the nine 5'-terminal exon 
of the gene coinc ide well with the nine-res idue amino terminal protein segments 
preceding the b radykin in moiety . These nine genetic doma ins were charac ter i /ed b\ a 
thr ice-repeated pattern of three genetic segments ; two sets of three segments, 
encompass ing exons 3-5 and exons 6-K, are more closely related to each other. Based 
on this s imilari ty be tween sets of genetic doma ins two success ive duplication 
mechan i sm were proposed as an evolut ionar \ ' model for the generat ion of the 
structure of the k in inogen gene (Ki tamura et al.. 1985). b rom the pattern ol ' internal 
homolog ies in the k in inogen heavy chain and its under ly ing gene it has been deduced 
that the second gene dupl icat ion event took place by internal rather than external 
h o m o l o g o u s recombina t ion . 
At the protein level, compar i son of the three internal repeats of the human 
kininogen heavy chain (cor responding lo protein doma ins 1 ) 1 1 - D 111) with those of 
smaller cyste ine prote inase inhibi tors such as stefin and cystatin ( M W 1 1-13 kl)a) has 
revealed an unexpec ted evolut ionary cognat ion be tween the var ious families of 
cysteine prote inase inhibi tors (Mul le r - l t s te r l et al.. 1985b). Kininogen repeats show 
signif icant sequence h o m o l o g y to the cystatin type of inhibitors, with the most 
p ronounced similar i ty found between the second and third repeat (1) II and 1) III), 
f h u s the k in inogen heavy chain is built by three c o n s e c u t i \ e c>statin like units in a 
head- to- ta i l or ientat ion. The s t e f in - type inhibi tors were found to be only distantl_\-
related to the k in inogen heavy chain repeats and more closely related to the c\ statins. 
On the basis of mutua l similari ty be tween these cogna te protein families, a 
hypothet ic mode l for evolut ion of the superfami ly of m a m m a l i a n cysteine proteinase 
inhibitors was cons t ruc ted (Fig. 1.5). ' f h i s model predicts that the \'ariel_\ of 
mammal i an cys te ine prote inase inhibitors arose f rom a pr imordial s tcf in- lype of 
inhibitor, wh ich represents the archetype of this supe r famih ' . f h e cystatin like 
inhibitor descended f r o m this progeni tor possibly by the fusion with another gene 
e lement c o m p l e m e n t i n g the primordial stefin gene. I ' hen in a gene dupl icat ion e \ e n t . 
an intermediate consis t ing of two cystatin like b locks were ibrmed. l '\entLiall\ 
Figure 1.5 Hypothetical schemes for the evolution of the superfamily of 
mammalian cysteine proteinase inhibitors including the kininogen heavy 
chain 
Filled boxes represent relevant segments of the protein sequence 
ancestor of the stefm-type inhibitors; ancestor of the cystatin-
type inhibitors. HMWK heavy chain formed by three cysatin-like building 
blocks; K, kinin segment; L, the variable light chain of the kininogens 
(marked by broken lines). E l - E l 1 denotes exons 1-11 of the human kininogen 
gene. The site of exons E1-E3, E4-E6 and E7-E9 correspond to protein 
domains D l , D2 and D3 respectively. Solid bars indicate the repetitive protein 
segments of the heavy chain of highest internal homology (encoded by exons 
E3-E5 and E6-E8), which probably arose by internal homologous 
recombination. Asterisks mark the putative reactive sites. Left margin; open 
boxes indicate the three known families of mammalian cysteine proteinase 
inhibitors. 
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another gene duplication gave rise lo the present day form of the kininogen hcav_\' 
chain composed of three cystatin like building blocks (Miiller-Estcrl , 1985). 
Kininogen Genes 
The sequence of the mRNAs coding for the human (Takagaki et al., 1985). 
bovine (Kitamura et al., 1983) and rat kininogen (Nawa et al., 1983) were investigated 
by molecular cloning, sequence analysis of their corresponding cDNAs and the 
organization of the human kininogen gene (Kitamura et al., 1985) A part of the bovine 
kininogen gene was characterized by isolating genomic clones containing the 
respective genes. The MMWK and LMWK mRNA have identical sequences at their 5' 
untranslated region and the region encoding the signal peptide, H chain and 
bradykinin. but completely diverges after the 3' sequence encoding the 13"' amino 
acid distal to the bradykinin sequence. The human kininogen gene consists of 11 
exons encompassing about 27 Kb. Out of these 11 exons, the 9 exons at the 5' 
terminal region encode the major part of the common sequences for the HMWK and 
LMWK mRNAs. Exon 10 can be divided into two portions, the 5' portion termed 
exon lOuK which encodes the common bradykinin sequences for the HMWK and 
LMWK; the 3' portion termed exon IO i imw covers the mRNA sequence specific for 
HMWK. Exon 11 is located downstream from exon 10 with a small inter\ening 
sequence and precisely specifies the sequence unique to LMWK mRNA. 
Genomic cloning and DNA blot hybridization analysis of total ccllular DNA. 
indicated that only one kininogen gene is present in the human genome. The sequence 
5'~GTAAGT-3' located at the 5'cnd of exon lOuMwand the sequence 5'("fTACAG-3' 
flanking the 5' end of exon IOmmw corresponds to the consensus sequence for the 
donor and acceptor sites of RNA splicing, 'fhus a single gene encodes the HMWK 
and LMWK mRNAs and the use of different polyadenylation sites in combination 
with alternative RNA splicing is responsible for the generation of twd distinct l> pes of 
mRNA. A similar F^NA splicing mechanism has been found for the bovine kininogen 
(Kitamura et al., 1983). 
Analysis of the mRNAs and the gene for kininogens has demonstrated that 
alternative RNA processing e\'cnts play an important role in the generation of the 
functional diversity of kininogens. These mechanisms do not alter the structures of the 
amino-terminal domains and the bradykinin moiety in the resultant protein structures 
but do allow kininogen to perform an additional function in contact actix'ation 
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reactions. These multifunctional properties of kininogens serve to coordinate 
regulation of related physiological response. These properties give rise to feed back 
effect depending on when each function is generated and how long it remains active. 
This in turn might be dependent on differential expression of the kininogen mRNAs. 
(Muller-Esterl, 1986). 
PROTEIN MODIFICATION STUDIES 
Oxidative modification of total proteins has been described under many 
pathological conditions (Kwon et al., 1998). Proteins are critical targets of reactive 
oxygen species (ROS) because they are present inside and outside the cell in high 
concentrations and since many are catalytic in nature, modifications by free radicals 
may have an amplified effect on their activity i.e. susceptibility to proteolysis, 
inactivation, degradation and aggregation. Reactive oxygen species (ROS) are a group 
of very reactive, short-lived chemicals produced during normal metabolism or after an 
oxidative insult (Sun, 1990). ROS include superoxide anion, hydrogen peroxide, 
hydroxyl radical and organic peroxides (Sun, 1990). ROS at low concentration have 
been implicated in the regulation of several physiologic processes such as 
proliferation (Shibanuma et al., 1990) differentiation (Allen and Balin, 1989) 
apoptosis (Mignotte and Vaysseire, 1998) and senescence (De Haan et al., 1996). At 
high concentrations, ROS are highly cytotoxic by including DNA damage, lipid 
peroxidation and protein degradation (Sun, 1990) (Fig 1.6). 
The modification of amino acid residues by hydroxyl residues and superoxide 
radical and subsequent changes in enzyme activity have been used to identify residues 
that are crucial for protein function such as methionine, tryptophan, histidine and 
sulfhydryl groups (Garrison, 1968). Enhancement in the inactivation of certain 
enzymes by secondary radicals, such as peroxy radicals has been reported (Gee et al., 
1985). In general, the consequence of free radical modifications of enzymes is 
inactivation. It has been speculated that repair mechanisms may exist for several of 
the protein modifications (Wilson, 1983). Cellular reductants and antioxidants may 
replenish electron or hydrogen atom 'holes' after hydroxyl radical attack and cleave 
protein-disulphides (Wolf et al., 1986). 
Using BSA and Chinese-hamster ovary cell soluble proteins, Wolff and Dean 
(1986) had demonstrated the sensitivity of proteins to oxygen free radicals derived 
Figure 1.6 Factors that affect reactive oxygen species and the level of 
oxidatively modified proteins 
ROS generating system are known to modify proteins. 
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from y irradiation, metal ions and hydrogen peroxide. Dean et al (1989) had proposed 
that proline and histidine may be the major sites of damage during radical attack upon 
proteins, and they are transformed respectively to glutamate and aspartate. This was 
investigated using proteins biosynthetically labelled with radioactive proline or 
histidine as targets. Free radicals were generated by copper and hydrogen peroxide or 
y-radiolysis. Protein bound histidine was substantially converted to aspartate. Proline 
was also modified during the radical attack. Thus, histidine and proline are important 
sites of protein attack by radicals and protein cleavage may result from these 
reactions. 
Davies (1987b) has reported that proteins, which have been exposed to certain 
oxygen radicals, exhibited altered primary, secondary and tertiary structure and can 
undergo spontaneous fragmentation or increased proteolytic susceptibility. Similarly, 
previous studies (Davies and Delsignore, 1987; Davies, 1985; Levine, 1983; Chin et 
al., 1982) have shown that oxygen radicals and other activated oxygen species such as 
hydrogen peroxide can increase protein degradation in intact cells and intracellular 
organelles as well as in vitro systems. ROS may thus play an important role in cellular 
protein turnover. The available data indicates that active oxygen species may act by 
altering cell proteins and making them more susceptible to degradation by 
intracellular proteolytic systems (Davies, 1986; Davies, 1987a; Stadtman, 1986; 
Wolff etal., 1986). 
Under in vivo conditions large amounts of oxidants are released from 
phagocytes at the inflammatory sites in the host defense response against invading 
microorganisms. This activity is mostly attributed to macrophages, neutrophils (Birtin 
et al., 1988) and mast cells (Malaviya et al., 1994). These inflammatory oxidative 
processes are primarily used to kill foreign organisms. However, host proteins that are 
sensitive to oxidation e.g.ai-proteinase inhibitor (a | -PI) and plasminogen activator 
inhibitor-I, may also be affected so that they arc no longer functional, and result in 
exacerbation of the inflammatory response. 
Kininogens are also damaged by oxidative modification. Retzois el al (1987) 
found that in HMWK the rate of total histidine loss, measured by amino acid analysis, 
coincided with the loss of most of its ability to bind to factor XI and prekallikrein. 
The functional significance of tryptophan residue was directly demonstrated by 
reaction of human HMWK with N-bromosuccinimide. At pH 4.0 and at 2.5 molar 
excess of the reagent, all the three tryptophans were converted to the oxinodole 
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derivative, and the conversion was accompanied by a significant drop in procoagulent 
activity. The loss of activity has been attributed to the loss of HMWK binding 
capacity to factor XI and prekallikxein. Under physiological conditions (pH 7.35) 
where only a single tryptophan is exposed, oxidation of this residue halved the 
activity suggesting that this tryptophan residue is functionally important. Oxidation of 
all 3 tryptophan residues resulted in added drop in activity. N-bromosuccinimide 
affects tyrosine, and to lesser degree histidine residue also, however tyrosine was 
shown not to be functionally important. The amidation of two carboxyl groups of 
either aspartic or glutamic acid residues by ethylenediamine treatment to pH 5.5 also 
results in decrease in binding of HMWK to factor XI and prekallikxein. HMWK 
susceptibility to oxidation was also measured by its ability to be used as a source of 
kallikrein generated kinins. The model kinin containing heptadecapeptide 
ISLMKPPPGFSPFRSSR and ISL(MO)KRPPGFSPFRSSR (with or without the 
methionine sulfoxide residue) just upstream from the N-terminus of kinin 
demonstrated that processing at this site is markedly reduced with MO-peptide, 
suggesting that this residue subjected to oxidative modification in HMWK results in a 
decrease in the ability to be used as a substrate by kallikrein (Kozik et al., 1998). 
UNFOLDING STUDIES 
It is well known that the biological functions of a protein is strictly related to 
its three dimensional shape which is assumed to depend in principle, only on the 
sequence of amino acids, i.e. on the primary structure. Protein folding is therefore 
based on the interaction of relatively short stretches of the peptidic backbone to form 
complex domains. Much of what is currently known about protein folding and 
stability has been gleaned from theoretical and experimental investigation in small, 
monomeric proteins and protein domains ranging from 50 to 150 amino acids in size. 
Unfolding and refolding studies using chaotropic agents have given a wealth of 
information on the structure and biogenesis of proteins (Tanford, 1968). Solvent 
denaturation studies on monomeric proteins have been extremely rewarding in 
understanding protein structure. Studies on a number of model monomeric protein 
systems have helped in elucidating many important factors in protein folding 
reactions. It has been established that electrostatic interactions (Schreiber and Fersht, 
1995) hydrogen bonding (Alber et al., 1987; Koh et al., 1997; Hebert et al., 1998), the 
hydrophobic effect (Schreiber and Fersht, 1995), folding nuclei (Mirny and 
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Shakhnovich, 1999), and partially folded intermediate (Chamberlain and Marqusee, 
2000) play important roles in the process by which a single polypeptide chain 
acquires its secondary and tertiary structure. For several small globular proteins 
simple two state equilibrium transition curves have been successfully used to fit the 
data (Jaenicke, 1987a). However it has been pointed that the two state model complex 
is often too simplified version of a more complex unfolding pathway which includes 
the formation of a metastable intermediate indicated as "molten globule" ( Kuwajima, 
1989). The main features of this state are native like secondary structure and a 
fluctuating tertiary structure, which leads to slight increase of the protein volume and 
to a loosening of long-range intermolecular interactions (Creighton, 1990; Barrick and 
Baldwin, 1993). The presence of intermediates is rather important as they explain the 
hierarchy and the high rate of protein folding (Baldwin, 1990). 
Multimeric enzymes provide an attractive system for investigating self-
assembly of protein structures and for examining regulatory interactions between 
subunits. Quaternary structure constitutes one of the most complex levels of structural 
organization in biological macromolecules however relatively little information is 
available about the detailed mechanisms by which multimeric proteins acquire their 
higher order structure in vivo. Biophysical studies on several dimeric protein systems 
have provided some insight into the folding and assembly reactions of oligomeric 
proteins. The dimeric P22 arc repressor has been observed in both equilibrium and 
kinetic studies to fold according to a strictly two-state (folded and unfolded) 
mechanism (Schildbach et al., 1995). Equilibrium unfolding studies on the dimeric 
Escherichia Coli Trp repressor and on the dimeric dihydrofolate reductase from the 
hyperthermophilic bacterium thermotoga maritime also revealed two state folding 
behavior. Transient, partially folded intermediates were detected in kinetics studies on 
the folding reactions of these two proteins (Gloss and Mathews, 1990; Gittleman and 
Mathews, 1990; Dams and Jaenicke, 1999). Partially unfolded dimeric intermediates 
were detected in the case of alkaline phosphatase (Rao and Nagaraj, 1991) and 
phosphoglucose isomerase (Blackbum and Noltmann, 1981). Subunit dissociation 
leading directly to unfolded monomers (2-state denaturation) has been observed in the 
case of the arc repressor protein (Bowie and Sauer, 1989). Subunit dissociation 
leading to native monomers followed by unfolding of the mianomer (3-state 
denaturation) has been demonstrated in the case of A, repressor (Pabo et al., 1979) and 
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aspartate aminotransferase (Herold and Kirschner, 1990).In case of neurotrophins 
various homologous structure were distinguished by comparing their denaturation 
data (Timm et al., 1994). Equilibrium experiments with the dimeric-subunit of 
bacterial luciferase and the tetrameric lactose repressor protein revealed multistate 
unfolding mechanisms for these protein systems (Noland et al., 1999; Barry and 
Mathews, 1999). The folding pathways of several higher order multimeric protein 
systems including the trimeric tail spike protein, the tetrameric lactate dehydrogenase, 
and the hexameric UDP glucose dehydrogenase proceed through complex pathways 
involving multiple unfolding intermediates (Jaenicke, 1987b). These oligomers do not 
possess disulphide linkages. 
For proteins containing disulphide bonds unfolding and refolding is generally 
followed by reduction and oxidation of native disulphides (Anfmsen, 1973; Haber and 
Anfinsen, 1962). Unfolding of a protein containing disulphide can be achieved 
conventionally by either reduction of disulphide bonds in the absence of denaturant 
(reductive unfolding) (Creighton, 1979; Creighton, 1984; Jaenicke and Rudolph, 
1990; Li et al., 1995) or by denaturation (e.g GdmHCl) in the absence of reductant 
(disulphide-intact unfolding) (Radford et al., 1992; Houry et al., 1995). In the later 
case, the unfolded protein retains intact native disulphide. The pathway of reductive 
unfolding has been investigated with limited numbers of proteins (Creighton, 1979; 
Creighton and Goldenberg, 1984; Kuwajima et al., 1990; Ewbank and Creighton, 
1993; Mendoza et al., 1994; Li et al., 1995). Reductive unfolding in presence of 
denaturant has been applied to characterize the unfolding pathways of many 
disulphide-containing proteins, including hirudin (3 disulphides), tick anticoagulant 
peptide (TAP) (3 disulphides) and ribonuclease A (4 disulphides). The properties of 
these proteins were observed by applying denaturant and reductant in a two-step 
manner to unfold native protein. In an alkaline solution containing strong denaturant 
and thiol catalyst, the native protein unfolded to form a mixture of scrambled species 
(Chang, 1997). Role of disulphide bond in intersubunit interaction, protein function 
and structure was elucidated by following the unfolding pathway of red kidney purple 
acid phosphatase (KBPAP) MW 111 kDa, a homodimeric glycoprotein with only one 
disulphide bond, between Cys-345 residues of the two subunits. Intersubunit 
disulphide bond was found to contribute 25% of the overall stability of the dimer. 
Unfolding studies revealed that the protein undergoes unfolding through at least three 
intermediates (Cashikar and rao, 1996). 
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BIOLOGICAL ASPECTS 
A deficiency of HMWK leads to in vitro coagulation impairment without a 
corresponding in vivo hemostatic disorder (Colman et al., 1975). No clinical 
abnormalities have been associated with a deficiency of HMWK and LMWK. 
However, a large body of evidence supports the important role of HMWK in body 
defenses. The coagulation system and thus HMWK are known to be involved in 
human pathological states including endotoxemia (Mason, 1988) adult respiratory 
distress syndrome (Carvolho et al., 1988) hyperacute renal allograft rejection (Colman 
et al., 1972) and extracorporal bypass (Watchfogel et al., 1990). Among the 
pathological entities, hypotensive septicemia has been studied the most because it is 
leading cause of death within intensive care units in the USA 
{Mortal.Morh. Weekly. Rep. 1990). 
Despite medical advances in the areas of antibiotics, blood volume restoration, 
cardiotonic medications and vasopressors, about 50% of the patients fulfilling the 
criteria of septic shock die due to one or more of the major complications such as 
hypotension and disseminated intravasucular coagulation, which leads to multiple 
organ failure. 
Experimental sepsis involving lethal endotoxin in baboons, a monoclonal 
antibody directed against factor XII (the first component of the blood coagulation 
system) significantly decreased the incidence of mortality and prevented the fall in 
blood pressure and the drop in the levels of HMWK (Pixley, 1990). A direct 
correlation has been found between the drop in functional HMWK levels and the 
development of hypotension. Factor XII becomes activated by bacterial products to 
form factor Xlla, resulting in initiation of coagulation events. Prekallikrein. is 
activated to form kallikrien, which induces kinin formation by clcaving HMWK. In 
endotoxemia, an efficient therapeutic approach proposed was to prevent generation of 
kallikrein, thus inhibiting the cleavage (and drop in levels) of kininogens that may 
contribute to hypotension (DeLa Cadena and Colman, 1991). 
Kininogens play a role in cardiopulmonary bypass as well. The procedure 
sometimes results in pulmonary dysfunction, which is thought to be mediated in part 
by neutrophil degranulation. Elevated levels of inactivated kallikrein complexes are 
found in plasma at the end of bypass (Watchfogel et al., 1987). Purified kallikrein can 
aggregate human neutrophils as well as induce their degranulation (Schapira et al.. 
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1982). The C-terminal portion of the HMWK Ught chain binds to the C-terminal 
region of the heavy chain of kallikrein and it has been postulated that HMWK serves 
as an acquired receptor for kallikrein on the surface of neutrophils. Since HMWK 
binds to neutrophils specifically and in a stable manner, a therapeutic strategy could 
be the use of HMWK light chain peptides to disrupt the binding of kallikrein or 
prekallikrein to HMWK and thus to neutrophils. Tliis intervention could prevent the 
destructive effect of kallikrein upon neutrophils during cardiopulmonary bypass. 
The synthetic peptide affinity label Phe-Gln-Val-Val-Cys-S-(3-nitro-2-
pyridinesulfenyl)-Gly-NH2 corresponding to the inliibitory and consensus sequence 
Gln-Val-Val-Ala-Gly present in HMWK and LMWK heavy chains is a selective 
inhibitor of platelet aggregation induced by plasmin (Puri et al., 1990). Plasmin 
formation after infusion of plasminogen activators, as well as active thrombin 
escaping inhibition by antithrombin (i.e. when bound to cells), is among the factors 
contributing to reocculusion after successful thrombolysis (Kakkar, 1988). The 
occurrence of such events is in about 15-25% of cases. Therefore the knowledge of 
HMWK structure can provide a basis for the design of inhibitors of coronary 
reocclusion after procedure such as thrombolysis and precutaneous transluminal 
angioplasty. 
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2. MATERIALS 
Chemicals used for the present study were obtained from the sources 
indicated. 
Genei, Banglore, India 
Molecular weight markers-PMW-H, PMW-M. 
Hi-Media, India 
Ascorbic acid, papain, sodium azide, uric acid. 
Merck-Schereherdt,Germany 
2-Mercaptoethanol 
Pharmacia Fine chemicals ,Sweden 
Blue dextran, Sephadex G-75. 
Qualigens Fine Chemicals, India 
Acetronitrile, ammonium persulfate, ammonium sulphate, bromophenol blue, 
disodium hydrogen phosphate, ethyl alcohol, glacial acetic acid, hydrochloric acid, 
methanol isopropanol, mannitol, monosodium dihygrogen phosphate, potassium 
iodide, sodium carbonate, sodium chloride, sodium hydroxide, sodium lauryl 
sulphate, sodium potassium tartarate, sulphuric acid, thiourea, trichloracetic acid, 
TEMED,(Tris (hydroxymethyl amino methane). 
Sigma Chemicals Co.USA 
Apofferitin (Horse spleen), D2O, Glucose oxidase, ficin, Sephacryl 300HR, 
ovalbumin, PVDF membrane, CAPS buffer. 
Sisco Research Lab (SRL) India 
Acrylamide, N ' N ' methylene bis-acrylamide, bovine serum albumin, casein, 
chymotrypsin, L-cysteine, commasie brilliant blue-R250, cytochromc C. DliAl: 
celluose, DTNB, EDTA, Folin ciocalteau;s phenol reagent, GdnHCl, glycine, phenol, 
ribonuclease, riboflavin, trypsin. 
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3. METHODS 
Purification of Sheep HMWK, LMWKl and LMWK2 
Sheep blood was routinely collected in plastic bottles containing (1/10 volume 
of acid citrate dextrose) at slaughter (within few minutes after the animal was killed). 
Following centrifugation at 1500 x g for 15 min in Sigma cooling centrifuge Model 
3K30 at 25°C the plasma obtained was used for isolation of HMWK and LMWK by 
the modification of method described by Sasaki et al (1981). The following steps were 
performed. 
Ammonium Sulphate Fractionation 
To 100 ml of plasma, ammonium sulphate was added with stirring, to make it 
40% saturated. After 2 hours the precipitate was removed by centrifugation at 2000 x 
g for 15 min at 4°C. To the supernatant, more ammonium sulphate was added to raise 
the final concentration to 60%. After 2 hours precipitate was collected by 
centrifugation at 2000 x g for 15 min and dialyzed extensively against several 
changes of the same buffer at 4 °C. 
Gel Filtration Chromatography 
Dialysate obtained was applied to a Sephacryl-300HR column (1.2x80 cm). 
The packed column was washed thoroughly with two bed volumes of operating buffer 
50 mM sodium phosphate buffer pH 7.5. In order to check uniform packing and to 
determine the void volume of the column, 2% (w/v) solution of blue dextran in 50 
mM sodium phosphate buffer, pH 7.5 was passed through the column. The volume of 
blue dextran and protein solution applied was not more than 2-3% of the total bed 
volume. 1.5 ml fractions were collected at a flow rate of 20 ml/h. Two protein peaks 
with papain inhibitory- activity were obtained. Fractions of first peak corresponding to 
HMWK were pooled. Homogeneity of the preparation was analyzed by 5% native 
PAGE. The second peak corresponding to LMWK was pooled and dialyzed 
extensively overnight against 5 liters of 50 mM sodium phosphate buffer pH 8.0. 
Ion-Exchange Chromatography 
Ten grams of DEAE cellulose was suspended in 15 volumes of 0.5 N 
hydrochloric acid for half an hour with constant stirring and washed in a Buchner 
funnel with distilled water. The washing was continued till the pH of the filtrate was 
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equal to 7.0. The exchanger was then treated with 15 volumes of 0.5 N sodium 
hydroxide for half an hour and again washed with distilled water till the pH of the 
filtrate-approached neutrality. The DEAE-cellulose was then resuspended in 
operating buffer (50 niM sodium phosphate buffer, pH 8.0) to get homogenous slurry. 
This slurry was poured on a vertically mounted glass column (2x10 cm) plugged with 
glass wool with the help of a glass rod. The column was left standing for one hour. 
Flow rate was subsequently adjusted with the help of stopcock until flow rate of 30 
ml/h was reached. The column was then equilibrated with excess of the operating 
buffer till the pH of the effluent was identical to that of the eluting buffer. Buffer was 
carefully removed from the surface and then the second inhibitory peak obtained from 
S-300HR (37 mg of protein) was applied on a DEAE cellulose column. After washing 
with 5 bed volumes of same buffer to remove unbound proteins, protein was eluted by 
a linear gradient of NaCl (0-0.3 M) using 50 mM sodium phosphate buffer (pH 8.0). 3 
mi fractions were collected at a flow rate of 40 ml/h. LMWKl and LMWK2 appeared 
well separated at -0 .25 M and -0 .27 M NaCl respectively. All purification procedures 
were performed at room temperature. 
COLORIMETRIC ANALYSIS 
Determination of Protein Concentration 
Protein was estimated by the method of Lowry et al (1951). Aliquots of 
protein solution were taken in a set of tubes and final volume was made upto 1 ml 
with distilled water. Five mi of alkaline copper reagent (containing one part of 1% 
(w/v) copper sulphate, and 2% (w/v) sodium potassium tartarate in 1% (w/v) sodium 
hydroxide and sodium carbonate) was added followed after 10 min of incubation at 
room temperature with 0.5 ml of 1.0 N Folin-Ciocalteu's phenol reagent. The tubes 
were instantly vortexed. The colour developed was read at 660 nm after 30 min 
against a reagent blank. A standard cur\c uas prepared using BSA as standard. 
Carbohydrate Estimation 
The procedure described by Dubois (1956) was followed. Two-milliliter 
aliquots containing 10to70 jig of carbohydrate was pipetted into a test tube and 0.05 
ml of 80% (v/v) phenol was added. This was followed by the addition of 0.5 ml of 
concentrated sulphuric acid, the stream of acid being directed against the liquid 
surface rather than against the side of the test tube in order to obtain good mixing. The 
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tubes were allowed to stand for 10 min, thoroughly mixed and again incubated for 20 
min at 30°C. The color intensity was measured at 490 nm for the quantitation of 
hexose content. Glucose was used as the standard. 
Thiol Group Estimation 
The procedure described by Ellman (1959) was followed for estimating the 
thiol groups of HMWK, LMWKl and LMWK2. SDS and 2-mercaptoethanoI were 
added to estimate free thiol groups in the purified proteins, which was then followed 
by titration with DTNB reagent. Aliquots of 0.2 ml containing 7 nmoles of HMWK, 
LMWKl and 2 alongwith denaturing agents (SDS and 2-mercaptoethanol) were 
mixed with 0.1 ml of DTNB reagent (prepared by dissolving 40 mg in 100 ml of 50 
mM Tris-EDTA buffer, pH 8.0 in a total volume of 3.1 ml. The absorbance was read 
after 15 min at 412 nm on Campspec Model M330 B spectrophotometer. Free thiol 
concentration was calculated from the absorbance using molar extinction cocfficicnt 
of 13,600 M"'cm'' for the thionitrobenzoic acid group released. A standard plot was 
prepared with different amounts of cysteine (0-64 nmoles) by the same procedure as 
described above for the estimation of -SH groups in the sample. 
Assay of HMWK, LMWKl and LMWK2 Inhibitory Activity' 
Inhibitory assay of HMWK was performed as described by Kunitz (1947). 
HMWK, LMWKl and LMWK2 were examined for their ability to prex'cnt thiol 
proteinases from digesting casein. For determination of inhibitory activity, papain was 
activated in the presence of 0.2 M EDTA and 0.5 M cysteine for 10 min prior to 
incubation with HMWK, LMWKl and 2 for 30 min at 37°C in 50 mM sodium 
phosphate buffer, pH 7.5.The enzyme inhibitor complex was further incubated with 
casein for 30 min at 37°C. The reaction was stopped by addition of 1.0 ml of 10 % 
TCA. Acid insoluble material was removed by centrifugation at 2500 rpm for 15 min. 
The supernatant was analyzed for acid soluble peptides, by the method of Lowry ct al 
(1951). 
Reduction and Reoxidation of Sheep HMWK 
HMWK was incubated with 0.14 M 2-mercaptoethanol for 5 min at room 
temperature. The solution was divided in two portions. Half of the reduccd HMWK 
was dialyzed against 50 mM sodium phosphate buffer pH 7.5 for 24 hours at 4°C to 
achieve air oxidation. The inhibitory activities of both reduced and reduced-
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reoxidized HMWK were determined by using activated papain with no reducing agent 
to avoid the effect of the reagent on disulphide bonds in the kininogen molecules. The 
process of reoxidation was followed on 5% SDS- PAGE. 
Assay of Caesinolytic Activity of Bromelain and Ficin 
The proteolytic activity of bromelain was measured according to the method 
of Murachi and Neurath (1960). The enzyme was activated at 37°C for 10 min in the 
presence of 20 mM cysteine. Then the volume was made upto 1 ml by sodium 
phosphate buffer pH 7.5. One ml of 0.5% casein was added and incubated for 30 min 
at 2TC. The reaction was stopped by 1.0 ml TCA (5%). Acid insoluble material was 
removed by centrifugation at 2500 rpm for 15 min. The supernatant was analyzed for 
acid soluble peptides by the method of Lowry et al (1951). 
SLAB GEL ELECTROPHORESIS 
Polyacrylamide Gel Electrophoresis (PAGE) 
Electrophoresis was performed by method of Laemmli (1970) using the slab 
gel apparatus manufactured by Biotech, India. Concentrated stock solution of 30% 
acrylamide containing 0.8% bisacrylamide and 1.5 M Tris, pH 8.8 were mixed in 
appropriate proportions to give the desired concentration of gel. It was then poured 
into the mould formed by the glass plates (8.5x10 cm) separated by 1.5 mm thick 
spacers. Bubbles and leaks were avoided. A comb-providing template for seven 
sample wells was inserted into the stacking gel solution before polymerization began. 
The polymerization was complete in about 30 min after which the comb was removed 
and wells overlaid with running buffer. Routinely, a 5% and 7.5% acrylamide gels 
were used. Samples containing 20-40 of protein mixed with equal volume of 
sample buffer (62.5 mM Tris HCl pH 6.8, 10% (v/v) glycerol and 0.001% 
bromophenol) as tracking dye was applied to the wells. Electrophoresis was 
performed at 100 V in the electrophoresis buffer containing 192 mM glycine and 25 
mM Tris-HCl pH 6.8 until the tracking dye reached the bottom of the gel. 
SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis was essentially 
performed by the Tris-glycine system of Laemmli (1970) using slab gel 
electrophoresis apparatus. Concentrated stock solution of 30%) acrylamide containing 
0.8% bisacrylamide and 1.5 M Tris, pH 8.8 were mixed in appropriate proportions to 
give the final required percentage. Protein samples were prepared in solution 
containing 62.5 mM Tris-HCl pH 6.8, 10% v/v glycerol, 2% (w/v) SDS, 5% (v/v) 2-
mercaptoethanol and 0.001% (w/v) bromophenol blue. The samples were incubated at 
100°C for 5 min. Electrophoresis was performed at 100 V till the tracking dye reached 
the bottom of the gel. Running buffer used during electrophoresis contained 1% SDS 
in addition to 192 mM glycine and 25 mM Tris-HCL pH 6.8. 
Staining of the Gel 
Commassie Brillaint Blue Staining 
After electrophoresis was complete the gels were removed and the protein 
bands were visualized by staining. The gel was stained with five gel volumes of 
0.25% commassie brilliant blue R-250 in 50% methanol and 10% acetic acid for at 
least 4 hours. For destaining, the gels were incubated with shaking in 5% methanol 
and 7.5% acetic acid at room temperature. 
MOLECULAR WEIGHT DETERMINATION 
The molecular weight of HMWK, LMWKl and LMWK2 was determined 
under native and denaturing conditions by gel filtration chromatography and SDS-
PAGE respectively. 
The molecular weight of native HMWK, LMWKl and 2 was computed from 
its elution volume on a SephacryloOOHR (1.2x85 cm) and Sephadex G-75 column 
(2x70 cm). S-300HR column was calibrated by determining the elution volume of 
following marker proteins. Apoferritin (MW 350 kDa), Glucose Oxidase (MW 150 
kDa), Bovine serum albumin (MW 68 kDa), ovalbumin (MW 45 kDa). Sephadex G-
75 column was calibrated by determining the elution volume of the following marker 
proteins. Bovine scrum albumin (MW 68 kDa). Ovalbumin (MW 45 kDa), 
Ribonuclease (MW 12 kDa) and Cytochrome C (MW 11.7 kDa). This data was 
analysed according to the theoretical treatment of Andrews (1964) method. The linear 
plot between Ve/Vo and log M was used in calculating the molecular weight of 
HMWK, LMWKl and LMWK2 where Vc is the elution volume of the protein and Vo 
is the void volume of the column determined by using blue dextran. 
Molecular weight of HMWK under denaturing conditions was calculated by 
the procedure of Weber and Osborn (1969) using SDS PAGE. The mobilities of 
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marker proteins determined under identical conditions was plotted against the 
logaritlinis of molecular weight. The standard proteins used were Rabbit Myosin 
(MW 205 kDa), Phosphorylase b (MW 97 kDa), Bovine serum albumin (MW 68 
kDa), and Ovalbumin (MW 45 kDa). The analysis of data indicated a linear 
relationship between log M and relative mobility (Rm) and the plot was used in 
calculating the molecular weight of HMWK. For the molecular weight determination 
of LMWKI and 2 the markers used were Phosphorylase b (MW 97 kDa), Bovine 
serum albumin (MW 68 kDa), Ovalbumin (MW 45 kDa), Carbonic anhydrase (MW 
29.1 kDa), Soyabean Trypsin Inhibitor (MW 20 kDa). 
N-TERMINAL ANALYSIS 
Sequencing was performed on a Shimadzu PPSQ-21 sequencer, which 
employs Edman degradation to sequentially cleave and identify amino acids starting 
at the amino terminus (N-terminus) of the protein. The highly purified protein was 
transferred to the PVDF membrane before the analysis. 
KINETICS OF INHIBITION 
Stoichiometry of Proteinase Inhibition 
Papain was used for the titration of HMWK, LMWKI and 2. For this 
experiment activated papain (0.06 fiM) was incubated for 10 min at 37°C with 
increasing amounts of HMWK, LMWKI and 2 in 50 mM sodium phosphate buffer. 
pH 7.5 and pH 8.0 respectively in a final volume of I ml. One millilitre of 5 % casein 
was added to the mixture containing kininogen and was incubated for 30 min at 37''C. 
The reaction was stopped with 500 |il of 10% (v/v) TCA and the supernatant was 
analyzed for acid soluble peptides with Folin's phenol reagent as described by Lowry 
et al (I95I) . Identical experiments were carried out for the kininogens with ficin using 
casein as substrate (Kunitz, 1947; Murachi and Neurath, 1960). 
Kj Determination 
Ki determination was carried out according to the same procedure described 
by Pagano et al (1984) the only difference was that the enzyme and inhibitor 
concentrations were reduced to obtain a non-linearity of dose response curves. Thus 
papain was used at a concentration of 0.06 f,iM to react with HMWK, LMWKI and 2 
varying from 0.01 jiM to 0.24 ^M and measurement of residual activity was made as 
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described by Kunitz (1947) using casein as substrate. Four different substrate 
concentrations were used, equal to 0.5 Km, 1 Km, 2 Km and 3 Km. Results were 
analyzed by the steady state equation of Krupka and Laidler (1959) using a linearised 
equation of Henderson (1972). 
[I]c 1 + 
Km 
y 
Vo 
+ [E]o ( 1 ) 
where [I]o , [E]o and [S]o are the initial concentrations of inhibitor, enzyme and 
substrate, respectively. Vq is the velocity without inhibitor. The plot of [I]o/ (l-VjA^o) 
against VoA^i is a straight line, the slope of which gives 
^i(app) -
( r<; i ^ 
1 + 
Km 
(2) 
True Ki was obtained from the plot of Kj (app) against [S]o 
Determination of Association Rate Constants (K+i) 
K+i values were determined by monitoring the time-dependence of association 
under second-order conditions. 1:2 molar ratio of enzyme and inhibitor (0.06 ^M and 
0.03 |iM) were mixed in a total volume of 1 ml of buffer, pH 7.5 for HMWK and pH 
8.0 for LMWKl and 2 respectively. Residual activity was assayed as a function of 
time after 0, 2, 5, 10, 20, 25 and 30 min as described above. 
Association rate constant (K+i) was calculated assuming that the enzyme (E) 
and either of the inhibitors (I) react according to equation (3) and considering K.i to 
be low enough to neglect the reverse reaction during the initial part of the process; 
E + I o E l (3) 
K-i 
Thus, when initial concentrations of enzyme, [E]o and inhibitor [I]o are 
idcntica!, the integrated form of the equation giving association rate becomes; 
- = - - - + K . t (4) 
E [E]o " 
Determination of Dissociation Rate constants (K_i) 
Conditions for maximal association between the proteinase and either inhibitor 
were achieved before the reaction was shifted towards dissociation by adding excess 
of substrate, which binds all the free enzymes. Substrate induced dissociation was 
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monitored for HMWK with papain and llcin, for LMWKl and 2 with papain 
incubated for 30 min at 37°C. Excess substrate (6% casein) was added to the mixture 
for different time periods and then assayed for their enzymic activity as described 
above. 
On the basis of equation (3) the dissociation of EI complex obeys first order 
kinetics during the initial part of the reaction, i.e. when there is almost complete 
association. In this case the integrated form of the dissociation rate equation is given 
by 
In 
^ [E l ] 
= K. , t (5) 
JEI Jo , 
From which K.i and half-life of complex may be calculated by rearranging as follows; 
to 5 = 0.693/K., (6) 
Similar experiments for Ki determination, association and dissociation rate 
constants for ficin were carried out with either inliibitors using their respective 
substrates. 
SPECTRAL ANALYSIS 
Circular Dichroism Spectroscopy 
Far-UV CD measurements were made at room temperature (22±2°C) with a 
Jasco J-810 spectropolarimeter, precalibrated with 0.1% d-10 camphor sulphonic acid 
solution. The spectra were recorded with a scan speed of 50 nni min"' with a response 
of 2s. Each spectrum was recorded as an average of two scans. Measurements in the 
far-UV CD (200-250 nm) region were carried out in cells with 1 mm pathlength. 
Changes in the secondary structure of HMWK. LMWKl and LMWK2 (0.1 mg/ml 
concentration of inhibitors) on interaction with activated papain with a molar ratio of 
1:2 were monitored. Commercially available papain was further purified by passing 
through G 50-80 column (1.5x50 cm). Results arc c.xprcsscd in terms of (G)mrw 
(Schmid, 1990) 
_ OxlOOxMRW 
c x d 
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where 0 is the measured ellipticity in degrees, c is the protein concentration in mg/ml , 
d is the path length in cm, and MRW is the mean residue weight. The mean residue 
weight used was 110 in all cases. 
Fluorescence Spectroscopy 
Fluorescence measurements for complexes between HMWK, LMWKl and 2 
(10 fa.g/ml) and activated papain in a molar ratio of 1:2 were performed at 25±2°C in 
Hitachi F-2000 spectroflourimeter. The excitation wavelength (Xex) was 280 nm and 
emission wavelength range was 300-400 nm. Cells with I cm pathlength were used 
and samples were continuously stirred during measurements. Emission spectra of 
HMWK, LMWKl and 2 with papain were measured with excitation and emission 
bandwidth of 5 and 10 nm respectively. 
Absorption Difference Spectra 
Ultraviolet absorption difference spectra was measured for HMWK, LMWKl 
and 2 (200 ^g/3 ml) along with activated papain with a molar ratio of 1:2 at 25 ±2°C. 
Bandwidth of 1 nm on the 0.5 absorbance scale on Camspec model M330B 
spectrophotometer. Appropriate controls were run and corrections were made 
wherever necessary. 
MODIFICATION OF HMWK BY FREE IMDICALS 
Reaction of Photosensitized Riboflavin with HMWK 
HMWK (500 nmoles) was photo illuminated with increasing concentration 
of riboflavin (5 to 40 fxM) in a final volume of 1000 j^ l at room temperature (28-
30°C). Riboflavin was freshly prepared at 2 mM concentration in 50 mM sodium 
phosphate buffer pH 7.5. HMWK was photoilluminated for different time 
intervals (0-60 min) with 40 [iM riboflavin in a final reaction volume 1000 |il at 
room temperature. Further, HMWK was incubated with riboflavin for different 
time intervals in which H2O was replaced by D2O. For light incubations tubes 
were set at a distance of 1 cm from 40-watt cool fluorescent lamp. The light 
intensity was 0.768 milliwatt at a distance of 1 cm measured by a Model 35 lA-
Powermeter. 
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Riboflavin-HMWK Interaction in the Presence of Scavengers and 
Antioxidants 
HMWK (500 nmoles) treated with increasing concentration of riboflavin 
and different time intervals of incubation with riboflavin were examined by SDS-
PAGE using 4.5% gel essentially as outlined by Laemmli (1970). Different 
scavengers and antioxidants used in the incubation mixture (40 |a,M riboflavin and 
500-600 nmoles HMWK incubated for 1 hour) were sodium azide, potassium 
iodide, thiourea, mannitol, uric acid (25 mM) and ascorbic acid (100 mM). The 
inhibitory activity of HMWK against papain was monitored by the method 
described by Kunitz (1947). 
Tryptophan Oxidation 
The emission spectra of the inhibitor at 25°C in the region 300-400 nm 
were recorded (protein concentration 500 nmoles) after excitation at 280 nm. 
Tryptophan oxidation of protein incubated with riboflavin was monitored by loss 
of fluorescence peaks. Fluorescence emission spectra of HMWK incubated with 
riboflavin in presence of sodium azide, potassium iodide, thiourea, mannitol, 
ascorbic acid and uric acid were taken to determine the protective effects on 
tryptophan residues. 
Ditj'rosine Formation 
Dityrosine was assessed with intrinsic fluorescence spectroscopy. To 
investigate the dityrosine cross linkages involved in aggregation oxidized HMWK 
(500 nmoles) was concentrated and subjected to trypsin (10 |^g/ml) digestion for 
24 hours at 37°C and precipitated by a one third dilution (v/v) with 1.6 M 
perchloric acid (PGA). I'ollowing centrifugation at 4000 x g the supernatants was 
neutralized with 2 M NaOH. 'fhe neutralized PGA supernatant were next 
subjected to HPLG separation on a Bond pack G-18 column (5 }j.m: 4.6x25 cm). 
HPLC conditions were as follows. Flow rate 0.8 ml/min. Solvent A was 
methanol/water (25/75 v/v). Solvent B was acetonitrile/water (80/20 v/v) and both 
solvents contained 0.1% (v/v) trifluoroacetic acid. The elution program consisted 
of solvent A 100% from 0 to 10 min, solvent B at a gradient from 0 to 90% during 
10 to 20 min. Solvent B (100%) from 20 to 30 min. In order to detect dityrosine 
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the fluorescence excitation wavelength was 284 nm and the emission wavelength 
was 410 nm characteristics for dityrosine. Retention time was detected on 
comparison with authentic dityrosine standard, which was a kind gift from Dr. 
D.K.Patel, Scientist C, ITRC, Lucknow . 
Far UV-CD Spcctra of HMWK in Presence of Riboflavin 
Changes in the secondary structure of HMWK on incubation with 40 fiM 
riboflavin for 0, 10, 20, 30, 40, 50 and 60 min were monitored between 200-250 
nm with a protein concentration of 500 nmoles in a 1mm path lengthcuvette. 
UV Absorption Spectra 
Absorption spectra was carried out on Camspec spectrophotometer at 
28°C. The protein concentration for absorbance measurement treated with 40 }aM 
riboflavin for 1 hour was 1.30 (.miolcs. 
All the photoilluminated samples used for spectroscopic measurements 
were extensively dialyzed against 50 mM sodium phosphate buffer pH 7.5 before 
taking the spectra. 
UNFOLDING STUDIES 
Assay of Inhibitory Activity of HMWK in Presence of GdnllCl 
100 |ig/ml HMWK was incubated with varying concentrations of GdnHCl 
(0.1 to 3 M) for 1 hour and the remaining inhibitory activity against papain was 
calculated as mentioned earlier. Untreated HMWK inhibitory activity was taken 
as 100%. 
Fluorescence Emission Spcctra in Presence of GdnllCl 
Intrinsic fluoresccnce spectra were recorded b\' setting excitation 
wavelength at 280 nm, whereas emission spectra were collcctcd from 300 to 400 
nm. Excitation and emission slit widths were set at 5 nm. l-'or dcnaturation studies 
10 fig/ml HMWK solution as a function of varying concentration of Gdnl lCl (0-6 
M) were prepared by diluting 15 |xl of a 700 |ig/ml HMWK stock solution in 50 
niM sodium phosphate buffer pH 7.5. Each sample was mixed by vortexing and 
incubated for minimum 1 hour at 25°C before being evaluated. 
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Far UV-CD Monitored Dcnaturation 
Changes in the secondary structure of HMWK on incubating with varying 
concentrations of GdnHCl (0-5 M) was measured in the far UV region at 25oC 
using a bandwidth of 2 nm and a time constant of 2s. For denaturation 100 ^g/ml 
HMWK solution was studied as a function of GdnHCl concentration in 1mm 
quartz cell using the standard sodium phosphate buffer pH 7.5, 
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Figure 2.0 Gel filtration on Sephacryl-300HR column 
The ammonium sulphate saturated (40-60%) precipitate obtained from 100 ml 
of sheep plasma was dissolved and dialyzed against 50 mM sodium phosphate 
buffer pH 7.5. The dialysate containing 30 mg of protein was applied on S-
300HR column (1.2x80 cm) eluted with buffer at a flow rate of 20 ml/h. 1.5 
ml fractions were collected. Kininogen fractions were monitored by inhibition 
of the caesinolytic activity of papain , which were collected and further 
analysed. 
53 
RESULTS 
AMMONIUM SULPHATE FRACTIONATION 
The precipitate obtained between 40-60% ammonium sulphate saturation from 
sheep plasma was dissolved in 50 mM sodium phosphate buffer pH 7.5 and was 
dialyzed against the same buffer. 
GEL FILTRATION 
The dialyzed protein was subsequently chromatographed on Sephacryl-300HR 
column (1.2x80 cm). Two protein peaks were obtained. Papain inhibiting fractions of 
both the peaks were pooled concentrated and checked for purity. First peak 
corresponded to HMWK and the second peak to LMWK (Fig. 2.0). A total of 8.0 mg 
of HMWK with 119-fold enrichment having a yield of 14 % was purified (Table 2.0). 
Peak 1 was found to be homogenous, whereas peak second showed more than one 
band on native page (Fig. 2.3). 
ION EXCHANGE CHROMATOGRAPHY 
The pooled fractions of second. peak were further purified by linear salt 
gradient (0-0.3 M) on DEAE-cellulose column (2x10 cm) equilibrated with 50 mM 
sodium phosphate buffer pH 8.0. Two protein peaks with papain inhibiting capacity 
were obtained corresponding to LMWKl and LMWK2, which were found to be 
homogenous on native page. LMWKl and LMWK2 appeared well separated at -0.25 
M and -0 .27 M NaCl respectively (Fig. 2.1). A total of 2.5 mg and 5.5 mg of 
LMWKl and LMWK2 with 148 and 128 fold enrichment and yield of 5.63% and 
10.63% were purified respectively (Table 2.0). 
HOMOGENEITY 
Homogeneity of the resulting HMWK, LMWKl and LMWK2 preparations 
were assessed by electrophoretic techniques. The purified HMWK gave a single band 
on native polyacrylamide gel electrophoresis (PAGE) (5%) as shown in Fig 2.2. 
LMWKl and LMWK2 gave single bands on native PAGE (7.5%) (Fig. 2.3). 
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Figure 2.1 Ion-exchange chromatography on DEAE celhilose column 
Second peak of kininogen obtained from S-300HR was repeatedly collected 
and further purified by ion exchange chromatography on DEAE cellulose 
column (2x10 cm) equilibrated with 50 mM sodium phosphate buffer pH 8.0. 
3 ml fractions were collected using a linear gradient of 0-0.3 M sodium 
chloride at a flow rate of 40 ml/h. Each fraction was assayed for thiol 
proteinase inliibitory activity using casein as substrate. Two inhibitory peaks 
corresponding to LMWKl and LMWK2 were obtained 
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Figure 2.2 Gel electrophoresis of sheep HMWK during various stages of 
purification 
Electrophoresis was carried out on a 5% non-denaturing gel as described 
under methods. Lane a, contained 40-60% ammonium sulphate saturated 
plasma, Lane b, contained 40 i^g of purified HMWK obtained from S-300HR. 
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Figure 2.3 Gel electrophoresis of sheep LMWKl and LMWK2 during 
various stages of purification 
Electrophoresis was performed on 7.5% non-denaturing gel as described 
under methods. Lane c, contained pooled fractions of peak II obtained from S-
300HR. Lane a and b contained LMWKl and LMWK2 respectively, obtained 
after ion exchange chromatography on a DEAE cellulose column. 
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Figure 2.4 Molecular weight estimation of purified sheep HMWK using 
S- 300HR gel filtration chromatography (Andrews method) 
Purified sheep HMWK was applied on a column of S-300HR (1.2x80 cm) 
eluted with 50 mM sodium phosphate buffer pH 7.5 at a flow rate of 20 ml/h. 
The molecular weight markers used were appoferitin (480 kDa, AF), glucosc 
oxidase (150 kDa, GOD), bovine serum albumin (68 kDa, BSA), ovalbumin 
(45 kDa, Ova). The position of the elution of HMWK is indicated with an 
arrow. 
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PROPERTIES OF PURIFIED HMWK, L M W K l AND L M W K 2 
Molecular Weight 
The molecular weight of sheep HMWK was determined under native as well 
as denaturing conditions. Under native conditions, the molecular weight of HMWK 
was determined by gel filtration on S-300HR. The marker proteins apoferritin (450 
kDa), glucose oxidase (150 kDa), bovine serum albumin (68 kDa) and ovalbumin (43 
kDa) were chromatographed on a column of S-300HR (1.2x80 cm) equilibrated with 
50 mM sodium phosphate buffer pH 7.5 and their elution volume was determined. 
Analyses of the data indicated linear relationship between log M and VeA^o, by 
method of Andrews (1964), where Ve is the elution volume of a protein and Vq is the 
void volume of column. VeA^o of native HMWK corresponded to apparent molecular 
weight of 350 kDa (Fig. 2.4). Molecular weight of HMWK under denaturing 
conditions was calculated from its mobility on SDS-PAGE (5%) by the procedure of 
Weber and Osborn (1969). The mobilities of marker proteins were plotted against the 
logarithm of their molecular weight. The least square analysis of the data indicated a 
linear relationship between log M and relative mobility (Rm)- The position of 
migration of HMWK corresponded to 280 kDa (Fig. 2.5 A). 
When purified HMWK was analyzed by SDS-PAGE in presence of 2-
mercaptoethanol, the purified protein gave a single band with higher mobility 
corresponding to a molecular weight of 140 kDa (Fig. 2.5 B). This indicates that 
HMWK migrates as a dimeric form during purification and also on SDS-PAGE under 
non- reducing conditions. Under reducing conditions, the dimeric form is converted to 
monomeric form (MW 140 kDa) suggesting that the dimers are disulphide linked. The 
molecular weight of HMWK was estimated from its relative mobility in comparison 
with those of standard proteins reduced with 2-mercaptoethanol. 
Molecular weight of native LMWKl and LMWK2 was determined using gel 
filtration on Sephadex G-75 (2x70 cm). The marker proteins phosphorylase b (97.4 
kDa), bovine serum albumin (68 kDa), ovalbumin (43 kDa), chymotrypsin (26 kDa), 
ribonuclease (12.7 kDa) were chromatographed on a column of Sephadex G-75 
equilibrated with 50 mM sodium phosphate buffer, pH 8.0 and their elution volume 
was determined. Ve/Vo of native LMWKl and LMWK2 corresponded to apparent 
molecular weight of 68 kDa (Fig. 2.6). Both LMWKl and LMWK2 gave a single 
band on SDS-PAGE under reducing conditions corresponding to MW of 68 kDa (Fig. 
2.7). 
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Figure 2.5 Molecular weight determination of purified sheep HMWK by 
SDS- polyaerylamide gel electrophoresis in presence and absence of 2-
mercaptoethanol. 
Electrophoresis was carried out on a 5% gel. A.40 |_ig of IIMWK (Lane a) was 
examined in absence of 2-mercaptoethanol. B. 40 ).ig of HMWK on reduction 
by 2-mercaptoethanol was examined (Lane b). For both gels, A (Lane b), B 
(Lane a) the following standard marker proteins were used. Rabbit yosin (MW 
205 kDa), 2. Phosphorylase b (MW 97 kDa), 3. Bovine serum albumin (MW 
68 kDa). Inset; Log M versus relative mobility (R,,,) of molecular weight 
markers: 
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Figure 2.6 Molecular weight estimation of purified sheep L M W K l and LMWK2 
using G-75 gel filtration chromatography (Andrews method) 
Purified sheep LMWKl and 2 were applied on a column of G-75 (2x70 cm) eluted witii 
50 mM sodium phosphate buffer, pi I 8.0 at a How rate of 30 nil/h. The molecular weight 
markers used were phosphorylase b (97.4 kDa, Ph), bovine serum albumin (68 kDa, 
BSA), ovalbumin (45 kDa, Ova), ehymotrypsin (26 kDa, Chy), ribonuclease (12.7 kDa, 
Ribo) The position of the elution of LMWKl and 2 is indicated with an arrow. 
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Figure 2.7 SDS polyacrylaniidc gel eleelrophoresis of LMWKl ami LMWK2 under 
reducing conditions. LMWKl and 2 were examined In presence of 2- niercaploelhanol 
on 7.5% gel. The following standard marker proteins were used. Lane a, l.Phosphorylase 
b (MW 97 kDa) 2.Bovine serum albumin (MW 68 kDa), 3.Ovalbumin (MW 45 kDa) 
4.Carbonic anhydrase (MW 29.1 kDa), 5.Soyabean Trypsin inhibitor (MW 20 kDa). Lane 
b and c contained LMWKl and LMWK2 obtained after ion exchange chromatography on 
a DEAE cellulose column. 
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Figure 2.8 Reduction and reoxidation of H M W K 
A 800 i^g/ml of HMWK was incubated with 0.14 M 2-mercaptoethanol for 5 
min. Inhibitory activity of reduced HMWK against papain, using 2% cascin as 
substrate was measured at different time intervals. 
B Reduced HMWK was dialyzed overnight with three changes of 50 mM 
sodium phosphate buffer pH 7.5 for the removal of 2-mercaptoethanol. 
hihibitory activity of reduced-reoxidized HMWK against caesinolytic activity 
of papain was measured during different time intervals of reoxidation. 
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Reduction and Rcoxidation of H M W K 
HMWK was reduced with 0.14 M 2-mercaptoethanol. The reduced sample 
was dialyzed against a large volume of 50 mM sodium phosphate buffer pH 7.5 
without any reducing reagent for 24 hours at 4°C to achieve reoxidation. The 
inhibitory activity of reduced-reoxidized HMWK was estimated by using activated 
papain as a target proteinase. Inhibition of papain by native HMWK was taken as 
100%, which decreased to 2% on reduction (Fig. 2.8 A). However after reoxidation of 
the preparation the inhibitory activity was recovered to 100% (Fig. 2.8 B). The 
electrophoretic profiles of reduced and reduced-reoxidised HMWK on 5% SDS 
PAGE indicated that the reduced and reoxidized states of HMWK corresponded to 
monomeric and dimeric forms (Fig. 2.9). Further the inhibitory profiles indicated that 
only dimeric forms of HMWK are able to inactivate the caesinolytic activity of 
papain. 
Stokes Radius 
The stokes radii of HMWK, LMWKl and 2 were determined from their 
elution volumes from S-300HR column and Sephadex G-75 column calibrated with 
several globular proteins of known stokes radii. The data was analyzed to the 
theoretical treatment of Laurent and Killander (1964) equation. 
Kav =Ve-VoA^t-Vo 
where Ve = elution volume, Vo = void volume and Vt = total volume. The linear plot 
between stokes radius and [-log Kav] of the marker proteins were used for the 
calculation of stokes radius of HMWK. LMWKl and 2. Stokes radii calculated for 
HMWK, LMWKl and 2 were found to be 44"A (Fig. 3.0 A) and 35.3°A (Fig. 3.0 B) 
respectively. 
pH Stability of I IMWK, LMWK 1 and LMWK 2 
Hffcct of pH on inhibitor)- activities of HMWK, LMWKl and 2 was examined 
at various pH values. As shown in Fig. 3.1, HMWK, LMWKl and 2 were stable in 
pH range 5.0 - 8.0. However their activity was significantly diminished below pH 5.0 
and above pH 8.5. 
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Figure 2.9 Electrophoretic patterns of rcduced-reoxidized H M W K on 
SDS PAGE 
Electrophoresis was carried out on 5% gel. Lane a, contains HMWK reduced 
with 0.14 M 2-mercaptoethanol. Lane b contains reduced HMWK alter 12 
hours of reoxidation. Lane c, contains reduced HMWK after 24 hours of 
reoxidation. 
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Figure 3.0 Determination of Stokes radius of the purified HMWK, 
LMWKl and LMWK2 by Laurent and Killander Plot 
A The purified HMWK was subjected to gel filtration on Sephacryl 3001!R. 
Kav values were computed from the elution volume of marker proteins. 
Stokes radii for the marker proteins were appoferritin (AF, 59°A), bovine 
serum albumin (BSA, 35.5°A), ovalbumin (Ova, 27.3°A). The stokes radius 
for HMWK is indicated by a single arrow. 
B. Purified LMWKl and 2 were subjected to gel filtration on Scphadex Cj-75. 
Kav values were computed from the elution volume of marker proteins. 
Stokes radii for the marker proteins were bovine serum albumin (BSA. 
35.5°A), ovalbumin (Ova, 27.3°A), ribonuclea.se (Ribo, 19.2"A). cytochrome-
C (Cyt, 16.4"A). The stokes radius for LMWK 1 and 2 is indicated by a single 
arrow. 
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Figure 3.1 pH stability profile of sheep H M W K , L M W K l and L M W K 2 
(• )HMWK, (o) LMWKl and ( T ) LMWK2 each 50 |.ig/ml were incubated 
with 50 mM sodium acetate buffer pH 3.0-6.0, sodium phospliate buffer pll 
7.0-8.0 and 50 mM Tris HCl buffer pH 9.0 for 30 min at 37"C. After 
incubation, pH of the mixtures was neutraUzed and inhibition of caesinolytic 
activity of papain was measured. The procedure was same as described in 
'Methods section'. The activity of papain in the absence of inhibitor was taken 
aslOO%. 
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Figure 3.2 Thermostabilty profiles of HMWK, LMWKl and LMWK2. 
( . ) HMWK, (o) LMWKl and ( T ) LMWK2 each 50 |.ig/ml in 50 mM sodium 
phosphate buffer pH 7.5 and pH 8.0 respectively, were incubated at various 
temperatures ranging from 20 to lOO^ C^ for 30 min. After cooling at 0"C the 
remaining inhibitory activity against papain using casein as substrate was 
estimated. The procedure was the same as described in methods for the 
inhibition assay using casein as substrate. The inhibitory activity of the 
inhibitor at 37°C was taken as 100%. 
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Thermostability of HMWK, LMWKl and LM\VK2 
Sheep HMWK, LMWKl and 2 were incubated at various temperatures 
ranging from 20°C to 100°C for 30 min and remaining inhibitory activity was 
estimated. As shown in Fig. 3.2 sheep HMWK. LMWKl and 2 were stable up to 
70°C. These properties are similar to those of HMWK, LMWKl and 2 from human 
and bovine sources (Sasaki et al., 1981; Yumiko and Ohukobo, 1987). 
Carbohydrate Content 
All the three inhibitors were determined to be glycoproteins. Their neutral 
hexose content was determined by using phenol sulphuric acid method (Dubios et al., 
1956). HMWK, LMWKl and 2 corresponded to 7 |ig/ml of neutral hexose in 
HMWK, while it came out to be 3.5 ^g/ml for both LMWKl and 2. The 
corresponding value of carbohydrate content was found to be 4% and 2% for HMWK, 
LMWKl and 2 respectively. 
Sulfhydryl Content 
The sulfliydryl groups in HMWK, LMWKl and 2 were titrated against DTNB 
under native as well as denaturing conditions. No color was observed under native 
and denaturing conditions in HMWK, LMWKl and 2 indicating that no free 
sulfliydryl groups are present in either of the forms. However under reducing 
conditions (2-mercaptoethanol) HMWK absorbance at 410 nm was found to increase 
showing one mole of -SH group per one mole of monomeric HMWK. 
Inhibition of Thiol Proteinases by HMWK, LMWKl and LMWK2 
The inhibitory activities of sheep HMWK. LMWKl and 2 towards thiol 
proteinases papain, ficin, bromelain and serine proteinases, trypsin and chymolrypsin. 
were examined using casein as substrate. Ficin and papain were strongly inhibited 
whereas sheep HMWK, LMWKl and 2 did not inhibit trypsin, chymolrypsin and 
bromelain. Caseinolytic activity of ficin was sharply reduced as compared to papain. 
At 3 (ig / 20 ^g ficin there was more than 60%±2 inhibition of caesinolytic activity by 
HMWK. The maximal inhibition of ficin was 91%±1.2. However in case of papain 
there was 10% inhibition of caesinolytic activity at 3 i^g / 20 |ig enzyme. The 
maximal inhibition of papain was 85%±1.6 (Fig. 3.3). Similarly in case of LMWKl 
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Figure 3.3 Inhibitory activity of HMWK with different proteinases 
20 fj.g of thiol proteinases, papain, ficin, bromelian and serine proteinases, 
trypsin and chymotrypsin were incubated with varying concentration of 
HMWK, (0-14 i^g) for 60 min. Tlie inhibitory activity of HMWK, towards (o) 
Papain, ( • ) Ficin ( • ) Trypsin,(T) Chymotrypsin and (•) Bromelain was 
measured by using 2% casein as a substrate. 
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Figure 3.4 Inhibitory activities of LMWKl and LMWK2 with different 
proteinases 
20 f^g of thiol proteinases, papain, ficin, bromelain and serine proteinases, 
trypsin, chymotrypsin were incubated with varying concentration of LMWKl 
and 2, (0-14 |ag) for 60 min. The inhibitory activity of (A) LMWKl (B) 
LMWK2, towards (o) Papain, ( • ) Ficin ( • ) Trypsin, ( T ) Chymotrypsin, (•) 
Bromolain was measured by using 2% casein as a substrate 
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and 2 there was 30% decrease of ficin caesinolytic activity at 5|ig / 20fig enzyme. 
Only 10% decrease of papain caesinolytic activity was observed at 5 |ig / 20 |ig 
enzyme (Fig. 3.4). This indicated that sheep kininogens are more effective against 
ficin as compared to papain. 
KINETICS OF INHIBITION 
The stoichiometry of association of purified HMWK, LMWKl and LMWK2 
was determined by incubating a fixed concentration of papain with increasing 
concentration of inhibitor. Caseinolytic activity of papain using casein, as substrate 
was determined in the presence of HMWK, LMWKl and 2. A linear increase in 
inhibition upto 90% was observed in case of HMWK, LMWKl and 2 indicating a 
complete association between enzyme and inhibitor under these conditions. One mole 
of HMWK, LMWKl and 2 reacts with 2 mole of papain i.e. 1:2 stoichiometric ratio 
was obtained. 1:2 stoichiometry of human HMWK binding with papain had been 
earlier confirmed by Turk et al (1996b). 
Ki Determination 
Ki values have been determined after decreasing the papain, ficin and inhibitor 
concentration, which favored the dissociation of the complexes, and using the steady 
state equation derived by Krupka and Laidler (1959). 
rao 
Vo Km. 
Kj (app) was found to increase as a function of the substrate concentration for all the 
inhibitors. The true Ki values were obtained from a replot of Kj (app) against [S]. The 
Kj (app) value obtained for HMWK from the plot with papain and ficin was 0.8x10"^ 
M (Fig. 3.5) and 0.6x10"^ M (Fig. 3.6) respectively. The Kj (app) value is lowest for 
ficin indicating highest affinity for ficin. 
The Kj (app) value obtained for LMWKl and 2 from the plot with papain was 
2.4x10''^ M and 2.2 xlO"^ M (Fig. 3.7 A and Fig. 3.7 B) respectively, under conditions 
of routine assay system. 
ICso Value 
IC50 value is the concentration of inhibitor at which 50% of the enzyme is 
inhibited. The I C 5 0 values obtained with various thiol proteinases have been given in 
7 1 
Figure 3.5 Kj determination o f l l M W K with jiapain 
Papain was used at a final concentration of 0.06 |.iM with increasing 
concentration of HMWK (0.01 to 0.24 |iM) and measurement of residual 
activity was made as described in methods using cascin as substrate. I'our 
different substrate concentrations equal to, 0.5 Km, 1 Km, 2 Km and 3 Km 
with Km=2.88xl0' ' ' M. For the sake of clarity only the results obtained for 
[S]= 0.5 Km and [S]=2 Km are shown. 
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Figure 3.6 Kj determination of HMWK with ficin 
Ficin was used at a final concentration of 0.06 |xM with increasing 
concentration of HMWK (0.01 to 0.24 ^M) and measurement of residual 
activity was made as described in 'Methods section' using casein as substrate. 
Four different substrate concentrations were used, at substrate concentrations 
equal to 0.5 Km, 1 Km, 2 Km and 3 Km with Km=2.81xl0'^ M. For the sake 
of clarity only the results obtained for [S]= 0.5 Km and [S]=2 Km are shown. 
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Figure 3.7 A Ki determination o f L M W K l with Papain 
Papain was used at a final concentration of 0.06 (.iM with increasing 
concentration of LMWKl (0.01 to 0.24 f.iM) and measurement of residual 
activity was made as described in 'Methods section' using casein as substrate. 
Four different substrate concentrations were u.sed, at substrate concentration 
equal to 0.5 Km, 1 Km, 2 Km and 3 Km with Km=2.88x10"'' M. For the sake 
of clarity only the results obtained for [S]= 0.5 Km and [S]=l Km are shown. 
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Figure 3.7 B Ki determination of LMWK2 with Papain 
Papain was used at a final concentration of 0.06 j.iM with increasing 
concentration of LMWK2 (0.01 to 0.24 p-M) and measurement of residual 
activity was made as described in 'Methods section' using casein as substrate. 
Four different substrate concentrations were used, at substrate concentration 
equal to 0.5 Km, 1 Km, 2 Km and 3 Km with Km=2.88xl0'® M. For the sake of 
clarity only the results obtained for [S]= 0.5 Km and [S]=l Km are shown. 
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Table (2.1). The I C 5 0 values obtained for HMWK wim^papain and ficin was |iM 
and 0.012 ^M and I C 5 0 value for LMWKl and 2 was 0.010 ^M. 
Association Rate Constants (K+i) 
Association rate constants (K+i) were calculated for the two thiol proteinases 
assuming that the enzyme and either inhibitor react in such a way that dissociation 
rate is low enough to neglect the reverse reaction during the initial part of the reaction. 
The equation obtained was 
• + K „ t 
[E] [E], 
Data in Fig. 3.8 shows the plots of I/[E] versus time with papain and ficin. The slope 
of the straight lines obtained gives (K+i) which is 2x10'' M"'s"' and 4x10'^ M''s ' ' for 
HMWK respectively. The association constant for papain with LMWKl and 2 were 
computed to be 7.1x10"' M''s"' and 7x10' M"'s'' respectively (Fig. 3.9). 
Dissociation Rate Constants (K .|) 
The conditions for the dissociation were taken as the enzyme-inhibitor 
complex obeys first order kinetics during the initial part of the reaction. In this case 
the integrated form of the dissociation rate constant is given by 
lo" [EI] ^ 
loa 
[El] 
l E l l 
[EI]o 
0 y 
2.303 
K.| obtained with papain and ficin was 2xl0"\s ' ' , Ix 10"S"' for HMWK (Fig 4.0). K_i 
obtained with papain for LMWK land 2 was 17.04x]0'' s"' and 15.4x10"^ s"' 
respectively (Fig. 4.1). The kinclic parameters of HMWK. I.MWKl and 2 have been 
summarized in Table 2.1 
Half Life of the Complex 
Half life of the complexes were calculated by rearranging the equation 
0.693 
Ficin has longest half-life with HMWK as compared with papain (Table 2.1). 
Figure 3.8 Determination of association rate constants of H M W K for 
papain and ficin 
HMWK (0.03 i^M) at a molar ratio of 1:2 with thiol proteinases, A. papain 
and B. ficin (0.06 |iM) was incubated at 37°C and inhibitory activity (Vj) was 
measured as a function of time. The residual activity is plotted against time. 
Insets represent a plot of the data in accordance with equation. 
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TABLE-2.1: KINETIC CONSTANTS FOR T H E I N T E R A C T I O N O F H M W K 
L M W K l AND LMWK2 W I T H PAPAIN AND FICIN 
Ki(M) K-,(s-') Half life ICso 
of complex (jxM) 
PAPAIN 
HMWK 0.8x10"^ 2x10' 2x10"' 3.46x10^ .014 
LMWKl 2.4x10"^ 7.1x10' 17.04x10"' 4.06x10^ .010 
LMWK2 2.2x10-^ 7x10' 15.4x10"' 4.5x10^ .010 
FICIN 
HMWK 0.6x10"'' 4x10' 1x10"^ 6.93x10' .012 
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Figure 3.9 Determination of association rate constants of L M W K l and 
L M W K 2 for papain 
A. LMWKl and B. LMWK2 (0.03 |iM) at a molar ratio of 1:2 with papain 
(0.06 fj,M) were incubated and residual activity (Vi) was measured as a 
function of time for LMWKl and LMWK2. Tlie fractional activity is plotted 
against time. Insets represent a plot of the data in accordance with equation. 
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Figure 4.0 Determination of dissociation rate constants of HMWK with 
papain and ficin 
A Papain-HMWK (0.5 ^M), B Ficin-HMWK (0.5 \iM) complexes were 
preincubated for 30 min at 37°C before excess substrate was added to the 
mixture. Appearance of papain activity was recorded as function of time. 
Insets sliow plot of the data. 
e 1 
0.50 -
o > 0.25 ^ 
0 . 0 0 -
15 20 25 
Time (min) 
30 40 
Time (min) 
Time (min) 
50 60 70 
Figure 4.1 Determination of dissociation rate constants of LMWKl and 
LMWK2 with papain 
A. Papain-LMWKl and B. Papain-LMWK2 (l | iM) complexes were 
preineubated for 30 min at 37°C before excess substrate was added to the 
mixture. Appearance of papain activity was recorded as function of time. 
Insets show plot of the data. 
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N-TERMINAL ANALYSIS 
N-terminal analysis of LMWKI and LMWK2 resulted in the identical amino 
acid sequences of N-terminal, 10 amino acid residues. Examination of the homology 
of the N-terminus of LMWKI and 2 with other cysteine proteinase inhibitor in the 
available data gave 20% sequence homology with HMWK from porcine, bovine, and 
human LMWK (Table 2.2). 
SPECTRAL ANALYSIS 
Changes in the secondary and tertiary structure of HMWK, LMWKI and 2 on 
binding with papain were studied by ultraviolet absorption difference spectra, 
fluorescence emission spectra and far UV CD spectra. 
UV Difference Spectra of HMWK, LMWKI and LMWK2 with Papain 
Interaction of HMWK, LMWKI and 2 with papain was studied by UV 
difference absorption spectra at pH 7.5 and pH 8.0 in the wavelength region 250-300 
nm. Difference absorption spectra of HMWK, LMWKI and 2 (Fig. 4.2 and 4.3) with 
activated papain demonstrated that changes occur in the aromatic wavelength region. 
The spectra showed considerable maxima at 255 nm and minima at 280 nm for 
HMWK, LMWKI and 2. 
Fluorescence Spectra of HMWK, LMWKI and LMWK2 with Papain 
The fluorescence emission spectra obtained for HMWK, LMWKI and 2 gave 
emission maximum at 330 nm, 349 nm and 351 nm respectively, when excited at 280 
nm. Binding of HMWK to papain resulted in a decrease of the intensity and a 2 nm 
blue shift of the corrected tryptophan fluorescence emission spectrum (Fig. 4.4). In 
case of LMWKI and LMWK2-papain complex, a decrease in the intensity of the 
LMWKI and 2 was accompanied with a blue shift. This maximum shifted from 349 
nm to 347 nm for the LMWKl-papain and 351 nm to 349 nm for LMWK2-papain 
complex (Fig. 4.5). 
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TABLE-2.2: N-TERMINAL SEQUENCES OF SHEEP LMWKl AND LMWK2 
ALIGNED WITH OTHER KNOWN CYSTEINE PROTEINASE INHIBITORS 
Inhibitor 
(Source) Sequence References 
Sheep 
LMWKl D Q H K S 
Sheep 
LMWK2 D Q H K S 
Porcine 
HMWK E E S Q Q 
Bovine 
HMWK E E S - Q 
Human LMWK 
E I 
E I 
E I 
E I 
A 
A 
Q S 
Q S 
D - N 
D C N 
Q E S |Q S 
(Mashiko et al., 1998) 
(Sueyoshi et al., 1987) 
(Salvesenetal. . 1986) 
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Circular Dichroism Spectra of HMWK, LMWKl and LMWK2 Complexed with 
Papain 
Far UV CD spectrum of the purified HMWK is characterized by the presence 
of minima at 209 nm (Fig. 4.6). The results of CD PROT analysis shows that HMWK 
has a predominant P structure (57%), (23.5%) a-helical structure and only (18.9%.) 
random structure (Table 2.3). Both LMWKl and 2 have a clear negative peak at 208 
nm and 222 nm. CD PROT analysis shows that LMWKl has 23% a-helical structure, 
17% p-structure, 31% p-turns and 27% random structure and LMWK2 has 22% a-
helical structure, 21% P structure, 19%) P-turns and 36% random structure (Table 2.3). 
Complex of HMWK with activated papain resulted in complete loss of the secondary 
structure with positive ellipticity in the range of 205 nm-220 nm (Fig. 4.6). In case of 
complex between LMWKl and 2 with activated papain there was a slightly different 
pattern. LMWKl and 2 on interaction with acti\ aied papain resulted in 60% aiid 70%) 
loss of a-helical content respectively (Fig. 4.7). 
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TABLE 2.3: RELATIVE VALUES OF THE SECONDARY STRUCTURES 
PRESENT IN HMWK, LMWKl AND LMWK2 
Protein a-helix P-Structurc P-turn Random coil 
1.Native HMWK* 23.5% 57% 7% 18.9% 
2 . L M W K r 23.9% 17.4% 31.6%, 27.1% 
3. LMWK2* 22.9% 21.6% 19.6% 36.3% 
4.SubtiIisin BPN"" 15% 62% - 18% 
S.Nuclease* 29% 24% - 36% 
* This study 
* Provencher and Glockner (1981) 
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DISCUSSION 
Kininogens are large molecular mass cysteine proteinase inhibitors belonging 
to class 3 of the cystatin superfamily. These inhibitors are present in plasma and 
secretions of mammalian species. They are single-chain glycoproteins composed of 
an N-terminal heavy chain, a histidine rich fragment, the bradykinin moiety and a C-
terminal light chain. Bisulphide bridges interlink the heavy chain and light chain, hi 
mammals, three types of kininogen have been found differing in size, structure and 
functions. The largest kinin precursor commonly referred to as high molecular weight 
kininogen (HMWK) has a MW of 88-120 kDa, depending on its species origin (Kato 
et al., 1981; Hayashi et al., 1984). Among the smaller kininogens, low molecular 
weight kininogen (LMWK) with a MW of 50-70 kDa is found throughout the 
mammalian lineage. The third-type, T kininogen of MW 68 kDa seems to be unique 
to the rats (Okamoto and Greenbaum, 1983). 
Kininogens are multifunctional proteins that fulfill at least three distinct 
biological functions (Kato et al., 1981; Miiller-Esterl, 1986). They release kinins 
upon limited proteolysis by kallikrein like enzymes. HMWK mediates contact 
activation of the endogenous coagulation cascade. Deficiency of HMWK known as 
Flaujeac trait shows a prolonged clotting time of blood in vitro (Wuepper et al., 
1975). An unknown deficiency called Fitzgerald trait had been reported (Wadaman 
and Abraham, 1974) which subsequently was found to be due to lack of HMWK 
(Saito et al., 1975). 
Kininogens inhibit cysteine proteinases such as papain, cathepsins B, H, L, 
and ficin with high affinity. Cysteine proteinase inhibitors have important regulatory 
role in normal body processes involving cysteine proteinase activity which otherwise 
leads to excessive proteolysis and damage to tissues. Numerous pathological 
conditions have been associated to increased proteolytic activity of thiol proteinases 
including scptic shock (Assfalg-Machleidt et al., 1988), cancer progression (Sloane et 
al., as well as inflammatory reactions (Mort et al., 1984; Buttle et al., 1990; 
Cox and Eley, 1989). 
T kininogen is the major acute phase protein of the rats. In rats T kininogen is 
induced approximately 20 fold in response to an acute inflammation suggesting a key 
role in combating the condition (Anderson and Heath, 1985). 
Extensive work has been carried out for the purification and characterization 
of HMWK and LMWK using various isolation procedures. Purification of HMWK 
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and LMWK from human and bovine plasma has been reported by a number of 
workers (Pierce and Webster, 1966; Spragg and Austen, 1971; Hamberg et al., 1975; 
Sasaki et a!., 1977; Ryley, 1979; Nagasawa and Nakayashu, 1979; Nishikaze and 
Sakamoto, 1979; Muller-Esterl et al., 1982a). The purification procedures reported by 
many investigators (Thompson et al., 1978; Kerbiriou and Griffin, 1979; Erdos, 1979; 
Wuepper et al., 1975) includes ion exchange chromatography, gel filtration, 
immunoaffinity chromatography and starch block electrophoresis. Most of the 
workers extensively used a combination of many of these steps along with affinity 
chromatography using CNBr-activated chromagelA-2 (Sasaki et al., 1977), papain-
Sepharose 4B (Jarvinen, 1979), trypsin-chymotrypsin-chromagelA-2, CNBr-activated 
Sepharose CL 4B (Miiller-Esterl et al., 1982a) and CM papain-Sepharose (Gounaris et 
al., 1984). As most of these methods involve affinity chromatography, several 
chromatographic runs would be needed for the preparation of proteinase inhibitor in 
relatively large quantities. In general purification of HMWK and LMWK requires 
many steps and the recovery from plasma is reported to be very low. A major 
prerequisite for the understanding of two kininogens is the availability of both types 
of kininogens in homogenous form from different species, which also highlights the 
species difference. 
The isolation procedure used in the present study is simpler than that reported 
by Ryley (1979), Kato et al (1976) and Sasaki el al (1981) for purification of 
kininogens from bo\'inc and human plasma. By employing simple three step 
procedure involving ammonium sulphate fractionation (40-60%), gel chromatography 
on Sephacryl-300HR and ion exchange chromatography using DEAE-cellulose 
column, HMWK and two molecular forms of LMWK (LMWKl and LMWK2) have 
been purified and characterized. 
In the present study gel filtration on S-300HR separated the high molecular 
weight and low molecular Ibrms of kininogen. The llrsi protein peak cluted from S-
300HR was identified as HMWK and second peak corresponds to LMWK (I'ig. 2.0). 
The first peak corresponding to HMWK was puritled with relaliveh higii yield and 
fold purification (Table 2.0) as compared to HMWK puritled earlier from bovine by 
Komiya et al(1974). 
Homogeneity of HMWK was confirmed by the presence of single band in 
native-PAGE (Fig. 2.2). When SDS-PAGE of purified HMWK was performed under 
non-reducing conditions a single band was obtained at position corresponding to 280 
kDa (Fig. 2.5 A). This value was lower than the value obtained by gel filtration under 
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native conditions on S-300HR column which was found to be 350 kDa. (Fig. 2.4). 
The abnormal behavior in gel filtration may be due its glycoprotein nature. The 
carbohydrate content was found to be 3% in case of HMWK. The molecular weight 
of HMWK from different sources has been extensively investigated by various 
methods (Jacobsen, 1966). When bovine HMWK was subjected to gel filtration on a 
column of Bio GelP 300 a value of 300 kDa, was observed (Yano et al., 1971). Habal 
et al (1975) calculated a value of 210 kDa, by gel filtration in non-denaturing buffer 
and 108 kDa in 4 M-guanidine hydrochloride. They postulated that human HMWK 
exists as a dimer. 
Purified sheep HMWK gave a single band of MW 140 kDa under reducing 
conditions indicating that single chain molecule of HMWK moves as a dimer during 
purification steps and that the dimer is disulphide linked (Fig. 2.5 B). Our results are 
in tandem with the findings of Fligashiyama et al (1986) who reported that in case of 
humans HMWK molecule migrates as a dimer on SDS PAGF (MW 200 kDa) and 
under reducing conditions the dimeric form is converted to a monomer with an 
apparent MW of 100 kDa. Reduction and reoxidation of sheep HMWK indicates that 
an intermolecular disulphide bond forms the dimer since the dimers were observed in 
presence of SDS without a reducing agent. Dimers disappeared completely on 
addition of 2-mercaptoethanol and the reduced monomeric FIMWK was reconverted 
to the dimeric form by mild air oxidation (Fig. 2.9). A single disulphide bond links 
HMWK monomers. Complete recovery of inhibitory activity lakes place after 
reoxidafion of reduced HMWK (Fig. 2.8 B). These results indicate that this molecular 
interconversion is closely related with the inhibitory activit\' of IIMWK and the 
tertiary structure supported by disulphide bonds is necessary for the inhibitor)- activit>' 
of HMWK. 
The second peak obtained from S-300HR corresponding to LMWK (Fig. 2.0) 
showed heterogeneity on native-PAGE (Fig. 2.3, Lane c). which was further purified 
by anion exchange chromatography on DEAE cellulose column (I'ig. 2.1). Ywo 
protein peaks showing thiol proteinase inhibitory activity were obtained 
corresponding to LMWKl and LMWK2, which were found to be homogenous on 
native-PAGE (Fig. 2.3). Earlier isoelectric focussing of LMWK from human plasma 
had demonstrated that three major protein species with pi values of 4.45, 4.75. and 4.9 
are present but were not isolated (Nakanishi and Sakamoto, 1983). The yield of 
LMWKl (5.63%) and LMWK2 (10.65%) obtained by the present purification 
procedure (Table 2.0) was higher than that reported earlier by Nishika/.c et al (1979) 
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for the purification of LMWK from human plasma. LMWKl and 2 gave a single band 
of MW 68 kDa under reducing conditions (Fig. 2.7), which is same as the value 
obtained by gel filtration under native conditions on G-75 column (MW 68 kDa ) for 
both the inhibitors (Fig. 2.6). 
The pH stability and thermostability profiles shows that sheep plasma 
HMWK, LMWKl and 2 were stable in the pH range 5.0 to 8.5 incubated for 30 min 
(Fig 3.1) and were also found to be stable upto 70°C for 30 min (Fig 3.2). These 
properties for sheep plasma HMWK, LMWKl and 2 are similar to those of HMWK 
and LMWK from human and porcine (Sasaki et al., 1981; Yumiko and Ohukobo, 
1987). 
Nucleotide sequence analysis of cloned cDNA inserts had revealed the 
presence of two types of LMWK in bovine encoded by at least two very similar but 
distinct mRNAs. It had been reported that differences in the amino acid sequence 
were located within the internally homologous regions (Nawa et al., 1983). Amino 
acid analysis of sheep LMWKl and 2 resulted in the identical amino acid sequences 
of N-terminal 10 amino acid residues suggesting that the two proteins may have 
similar secondary and tertiary structure. Examination of the homology of the N-
terminus of LMWKl and 2 with other cysteine proteinase inhibitor in the available 
data gave 20% sequence homology with HMWK from porcine (Mashiko et al., 1998), 
bovine (Sueyoshi et al., 1987) and human LMWK (Salvesen et al., 1986) (Table 2.2). 
It is known that mammalian kininogens inliibit cysteine proteinases. Sheep 
plasma HMWK, LMWKl and 2 exhibited strong inhibition towards papain and ficin 
but did not inhibit trypsin, chymotrypsin and bromelain (Fig. 3.3 and 3.4).Various 
workers had studied the stoichiometry of inhibition of kininogens. Since domain 2 
and 3 have a sequence homology with other cysteine proteinase inhibitor the existence 
of two potential reactive sites in the heavy chain is reasonable and a 2:1 
(enzyme:inhibitor) stiochiometry would be expected (Ohkubo et al., 1984; Muller-
Esterl et al., 1985b). Nevertheless, the results of Gounaris et al (1984) pointed to 1:1 
stiochiometric ratio. This discrepancy was later explained by suggesting that (i) the 
inert reactive site might be buried in the kininogen molecule if it is in an intact state or 
one of the two potential reactive site binds with papain the other reactive site might be 
masked by the complex formation, resulting in an inert state (Sueyoshi et al., 1988). 
However purified sheep HMWK, LMWKl and 2 interact with papain and ficin in a 
molar ratio of 1:2. Our results are in accordance with the reports regarding kininogens 
that indicate a molar ratio of 2:1 for binding by using papain and ficin as proteinases 
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(Anderson and Heath 1985). Recently Turk et al (1996) confirmed 2:1 stoichiometry 
of human HMWK with papain. For LMWK it has been shown that the tighter binding 
site is that of domain 3, whereas the slower-binding, lower affinity site is in domain 2 
(Turke ta l . , 1996). 
HMWK, LMWKl and 2 are potent inhibitors of thiol proteinases, which is 
evident by their Kj (app) values that indicate HMWK has highest affinity for ficin 
than papain. Accurate Kj values were determined for kininogens by working at lower 
enzyme concentrations and using equation derived by Henderson (1972). It was 
readily apparent that the degree of inhibition varied with absolute concentrations of 
the inhibitor. Sheep HMWK inhibited papain and ficin with Kj value of 0.8 x 10"^ M 
(Fig. 3.5) and 0.6x10'^ M (Fig. 3.6) respecfively. The kinetics of association was 
determined for two thiol proteinases and the affinity of HMWK for ficin (4x10'' M''S" 
') was two times higher than that with papain (2x10''M"'S'') (Fig 3.8). Higher affinity 
for ficin is due to rapid association with the inhibitor whereas the rate of association 
to papain is slower. K-i obtained with papain and ficin for H M W K was 2x10"^ s"' and 
IxlO'^ s' ' respectively (Fig. 4.0 A B). The proteinases having low K j have high K+i 
and low K.i suggests that the stability of the enzyme inhibitor complex [EI] and 
complex formation is very rapid (Table 2.1). The IC50 values have been summarized 
in Table 2.1. HMWK has IC50 value of 0.014 ^iM and 0.012 ^M with papain and ficin 
respectively. Low IC50 values suggest a greater affinity for the inhibitor towards the 
enzyme. Hence the lowest value for ficin further justifies the higher affinity of the 
purified HMWK for ficin. 
LMWKl and LMWK2 inhibited papain with Kj value of 2.4x10"^ M and 
2.2x10-^ M respectively (Fig. 3.7 A and Fig. 3.7 B). The association rate constant 
obtained for papain was 7.1x10' M-'S"'and 7x10' M""S"' with L M W K l and 2 
respectively (Fig 3.9A B). LMWKl and LMWK2 have IC50 value of 0.01 (iM for 
papain. The data obtained gives comprehensive informafion about the kinetics of 
purified sheep kininogens with papain and ficin. 
The complcx spectroscopic changes accompanying the binding of HMWK, 
LMWKl and 2 with papain in near ultra violet region indicates that the environment 
of several aromatic amino acids in proteins has been perturbed by the interaction. The 
peaks in the absorption difference spectra are indicative of changes around tyrosine 
residues (Donovan, 1973). The broad peaks observed around 260 nm may partly be 
due to phenylalanine or cysteine residues and may also contain contributions from 
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tryptophan (Fig. 4.2 and Fig. 4.3). The fluorescence emission spectra of HMWK gave 
emission maximum at 330 nm. Complex of HMWK and papain caused a decrease in 
fluorescence intensity (Fig. 4.4). LMWKl and 2 gave emission maximum at 349 nm 
and 351 nm respectively.On binding with papain, these inhibitors resulted in a 
decrease in intensity (Fig. 4.5.). The decrease in intensity of HMWK, LMWKl and 2 
may be caused by shielding of aromatic residues in the inhibitor from solvent on 
binding with proteinase. They may also wholly or partly originate from local 
interactions affecting chromophoric groups of the proteins. 
Circular Dichroism (CD) is a convenient and widely used method for studying 
the conformational changes of globular proteins in solutions (Provencher and 
Glockner, 1981). The a-helical structure of the protein in far-UV region is 
characterized by negative peaks at 208-210 nm, 222 nm and a positive peak between 
190-192 nm (Jirgenson, 1970; Saxena and Wetlaufer, 1971, Chen et al., 1975). Far-
UV CD spectra of sheep HMWK shows a negative peak at 209 nm. Far UV-CD 
pattern of HMWK closely resembles that of subtilisin BPN' which has 15% a helix, 
62% p turn and 18% random structures (Pro\'encher and Glockner, 1981).CD 
spectrum of human HMWK in the far UV region shows the presence of a and (3 
secondary structure (Weisel et al., 1994). Far UV- CD spectra of LMWKl and 
LMWK2 show a negative peak at 208-210 nm and 222 nm (Fig. 4.7), The CD pattern 
of these inhibitors closely resembles that of nuclease, which possesses 29% a -helix, 
24% p turn and 36% random coils. 
HMWK on interaction with activated papain resulted in complete loss of 
negative peaks and a strong positi\'e peak is observed which is characteristic of 
random structure (Ramasarma et al.. 1994) (Fig. 4.6). In case of complex between 
LMWKl-papain and LMWK2-papain the a-helical content was reduced to 60% and 
70% respecti\'cly (Fig. 4.7). liarlicr studies for the interaction of rat cystatin a, 
chicken cystatin. human cystatin C, rcconibinant human c\statin A, with several 
proteinases reported no appreciable conformational adaptation of cither proteins 
(Takedaet al., 1986;Bjork etal.. 1989; I.indahl et al.. 1988; Stubbs et al., 1990; Pol et 
al., 1995). Precise information on the wa)' in which the molecules of peptidase and 
kininogens bind together must await the resuhs of X-ray crystallographic studies of 
the complex. 
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RESULTS 
EFFECT OF PHOTOILLUMINATED RIBOFLAVIN ON HMWK 
Riboflavin Induced Inactivation and Aggregation of HMWK 
Both HMWK and LMWK have identical heavy chain, possessing two cysteine 
inhibitory domains (Miiller-Esteri et al., 1985); therefore the effect of riboflavin 
exposure on the inhibitoiy activity was assessed only on HMWK. Its antiproteolytic 
potential was determined by the caseinolytic assay with papain. As shown in Table 
3.0 exposure of HMWK (500 nmoles) with increasing concentration of riboflavin (0-
40 |uM) resulted in rapid decrease of inhibitory activity. Results indicated 87%±3.4 
loss of inhibitory activity of HMWK towards papain on incubation with 40 )iM 
riboflavin for 60 min. Similarly increase in length of exposure (0-60 min) of HMWK 
(500 nmoles) with fixed concentration of riboflavin (40 |iM) resulted in 70%±2.5 loss 
of antiproteolytic activity within 30 min of incubation towards papain (Fig. 5.0). 
Samples of both native and treated inhibitor were also analyzed by SDS-PAGE. The 
detrimental effects of photodynamic action of riboflavin on HMWK are shown in Fig 
5.1. Untreated HMWK moves as a single band on SDS-PAGE 4.5%. HMWK treated 
with riboflavin still retains the original mobility, with a decrease in band intensity. An 
increase of aggregated products was observed with increasing concentration of 
riboflavin (0-40 fiM) as well as with increasing time periods of incubation with 
riboflavin (0-60 min). 
Involvement of Singlet Oxygen in Inactivation and Aggregation 
Riboflavin on photoillumination generates singlet oxygen, hydroxyl radicals 
and flavin triplet state (Joshi, 1985). To determine the type of reactive oxygen species 
(ROS) involved in aggregation, free radical scavengers and enhancer were used. In 
order to identif) whether singlet '02 is involved in the aggregation and inactivation, 
photooxidation reaction was carried out in H2O and D2O media to compare the extent 
of cross linking and inactivation in the presence of these media. Since the life time of 
singlet '02 is approximately 20 times shorter in H2O than in D2O (Merkel and Kearns, 
1972) therefore reactions involving singlet 'O2 are enhanced in D2O. As shown in (Fig 
5.2) the rate of HMWK aggregation was enhanced in D2O. Aggregated products were 
formed within 5 min of incubation and concomitant loss of native band was found to 
148 
< i^gure 5.0 Inactivation of HMWK by riboflavin as a function of 
ncreasing time in H2O and D2O 
Native HMWK (500 nmoles) was incubated with riboflavin (40 fiM) for 
ncreasing time periods (0-60 min) in a final volume of 1 ml at room 
emperature under fluorescent light. (0) HMWK was assayed for loss in 
mtiproteinase activity on incubation with riboflavin in water by caseinolytic 
issay. (A) Another sample of HMWK was incubated in presence of riboflavin 
•or increasing time periods in D2O. (•) Untreated HMWK is shown for 
comparison purposes. Values are mean of four independent determinations. 
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Table-3.0: LOSS OF ANTIPROTEOLYTIC ACTIVITY AFTER TREATMENT 
WITH INCREASING CONCENTRATION OF RIBOFLAVIN 
Conditions % HMWK activity 
Native HMWK 80 ± 7 . 8 
HMWK +5 |iM riboflavin 45 ± 2 . 6 
H M W K + 1 0 | l i M r iboflavin 30 ± 2 . 6 
HMWK +20 luM riboflavin 21 ± 1.5 
HMWK +30 i^M riboflavin 19± 1.6 
HMWK +40 [iM riboflavin 10± 1 
Concentrat ion of r iboflavin shown is as in the final reaction mixture. All incubations were in light for 1 
hour (28°C) in sodium phosphate buffer pH 7 .5 .HMWK activity was assayed by the method of Kunitz 
(1947). 
Results represent the mean ± S E M calculated from four separate experiments. 
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Figure 5.1 Photodynamic aggregation of HMWK with increasing 
concentration of riboflavin and time course of incubation 
A SDS polyacrylamide gel electrophoresis of HMWK (500 nmoles) incubated 
with increasing concentrations of riboflavin (0-40 |iM) for 1 hour. Lane a 
contains untreated HMWK, Lane b, c, d, e, f, g contains HMWK incubated with 
5 )iM, 10 |iM, 20 ^M, 30 iiM and 40 ^M riboflavin forlhour. 
B HMWK (500 nmoles) was incubated with riboflavin (40 |iM) for different 
time intervals. SDS polacrylamide gel electrophoresis (4.5%) was conducted. 
Lane a contains untreated HMWK, lane b, c, d, e, f, g contains HMWK 
incubated with riboflavin for 5, 10, 20, 30, 40 and 60 min. 
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Figure 5.2 A time course of aggregation of HMWK in 1)20 
HMWK (500 nmoles) was incubated with riboflavin (40 |.iM) in D2O for 
different time intervals. SDS polyacrylamide gel electrophoresis was 
conducted. Aggregates were formed within 5 min of incubation. Lane a, 
contains untreated HMWK, lane b, c, d, e, f, g contains HMWK incubated 
with riboflavin for 5, 10, 20, 30, 40 and 60 min. 
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Figure 5.3 SDS PAGE of treated HMWK along with different scavengers 
and antioxidants 
A. HMWK (500 nmoles) incubated with 40 (.iM riboflavin along with different 
antioxidants and scavengers (25 mM) in a final volume of 1ml for Ihour.Lane a 
contains untreated HMWK lane b, c, d, e, g, contains HMWK treated with 
riboflavin along with thiourea, mannitol, uric acid, sodium azide and potassium 
iodide respectively. Lane f contains riboflavin treated HMWK. 
B. Lane a contains untreated HMWK. Lane b contains HMWK incubated with 
riboflavin; lane c contains treated HMWK along with ascorbic acid (100 mM). 
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be increased. HMWK lost 75%±2.6 caseinolytic activity towards papain within 10 
min of incubation by the substitution of D2O for H2O, whereas HMWK still retained 
70%±2.2 inhibitory activity when the reaction was carried in H2O media (Fig 5.0). 
Further support for the role of singlet'O2 in photodynamic modification of HMWK 
was based on the fact that photoinactivation was greatly inhibited by sodium azide (25 
mM), which is supposed to be a good quencher of singlet'O2 (Dahl and Richardson, 
1980) whereas the presence of mannitol and thiourea, which are hydroxyl radical 
scavengers (Dahl and Richardson, 1980), had less effect on inactivation (Table 3.1). 
Protection of antiproteinase activity by KI, a triplet state quencher (Dahl and 
Richardson, 1980) (Table 3.1) was taken as an evidence for the involvement of triplet 
flavin state. Uric acid and ascorbic acid, which are known as biological antioxidants 
(Ames et al., 1981; Davies et al., 1990; Halliwell and Gutteridge, 1990; Mclord and 
Fridovich, 1969) were also used to determine their protective effects against 
photodynamic modifications. Among biological antioxidants, only ascorbic acid was 
able to protect antiproteinase activity (98%±2) effectively whereas uric acid showed 
only 48%±2.4 retention of inhibitory activity (Table 3.2). No aggregated products 
were observed in riboflavin treated HMWK in presence of sodium azide, potassium 
iodide, thiourea, mannitol and ascorbic acid (Fig. 5.3). However in the presence of 
uric acid, inhibition of aggregation was less effective (Fig 5.3 A). These results 
collectively suggest that HMWK photoinactivation and aggregation proceeds mainly 
via a singlet 'O2 pathway. 
Tri ptophan Oxidation of HMWK by Singlet Oxygen 
The fluorescence emission spectrum of riboflavin treated HMWK was 
completely quenched in the emission range 300 to 400 nm when excited at 280 nm, 
compared with untreated protein which had emission maximum at 330 nm (Fig 5.4). 
This was consistent with tryptophan oxidation. Sodium azide, potassium iodide and 
ascorbic acid, resulted in maximum retention of fluorescence emission. However the 
protective effects of mannitol, thiourea and uric acid were less pronounced (Table 
3.2). The protective effects of sodium azide and potassium iodide verify the 
involvement of singlet oxygen and flavin triplet state in tryptophan oxidation. 
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TABLE 3.1: PERCENT RESIDUAL HMWK ACTIVITY AFTER 
TREATMENT WITH RIBOFLAVIN (40 ^M) IN PRESENCE OF 
SCAVENGERS AND ANTIOXIDANTS 
Conditions Percent HMWK activitj' 
Native HMWK 100 ± 2 . 8 
HMWK + 40 i^M Riboflavin 20 ±1 
HMWK + Sodium azide (25 mM) 1 1 6 ± 7 . 8 
HMWK + Potassium iodide (25 mM) 80 ± 3 . 1 
HMWK + Thiourea (25 mM) 54 ± 3 6 
HMWK + Mannitol (25 mM) 60 ±1.2 
HMWK + Uric acid (25 mM) 48 ± 2 . 4 
HMWK +Ascorbic acid (100 mM) 98.1±2.0 
Concentrat ion of scavengers shown is as in the final reaction mixture. Ail incubations were in light for 
ihour (28°C) in 50 mM sodium phosphate buffer pH 7.5. H M W K activity was assayed as described by 
K u n i t z ( 1 9 4 7 ) 
Results represent the mean ± SEM calculated f rom four independent exper iments and are expressed as 
a percentage of the H M W K activity. 
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TABLE 3.2 RETENTION OF TRYPTOPHAN FLOURESCENCE IN 
PRESENCE OF DIFFERENT SCAVENGERS AND ANTIOXIDANTS 
Conditions % Retention of tryptophan fluorescence 
HMWK + Sodium azide (25 mM) 83 
HMWK + Potassium Iodide (25 mM) 71 
HMWK +Thiourea (25 mM) 45 
HMWK + Mannitol (25 mM) 50 
HMWK +Uric acid (25 mM) 40 
HMWK + Ascorbic acid (100 mM) 79 
H M W K (500-600 nmoles) incubated with 40 p M riboflavin for Ihour . Results are percentage retention 
of t ryptophan f luorescence emission intensity (which is dependent upon, but not synonymous with the 
number of t ryptophan residues) measured at 280 nm excitation and 300- 400 nm emiss ion with a slit 
width of 10 nm. Fluorescence studies were performed at pH 7.5 with 50 m M sodium phosphate buffer . 
Emission spectra of native H M W K was taken as 100% Values are mean of four independent 
determinat ions for which standard errors were less than 10%. 
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Figure 5.5 Dityrosine formation in treated HMWK 
Fluorescence emission spectra of untreated HMWK (500 nmoles) and riboflavin 
treated HMWK were excited at 325 nm and emission in the range of 410-420 
nm for dityrosine formation. ( — ) Corresponds to fluorescence emission 
spectra of native HMWK, ( ) emission spectra of HMWK treated with 
riboflavin. 
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DITYROSINE FORMATION 
To characterize the nature of covalent Hnkages in aggregates, dityrosine cross 
linkages were assessed by intrinsic fluorescence spectroscopy and HPLC analysis. 
There was an increase in emission of oxidized protein in the range 410-420 nm wiien 
excited at 325 nm (Fig. 5.5), which is an indication of dityrosine formation. HPLC 
analysis of aggregated HMWK was done to confirm the involvement of dityrosine 
linkages in aggregation. Oxidized HMWK was incubated with trypsin and subjected 
to perchloric acid precipitation (PCA). Trypsin and chymotrypsin are known to 
produce 3-4 fold increase in dityrosine release (Giulivi and Davies, 1993). PCA 
soluble peptides after a series of HPLC steps provided a peptide with a fluorescence 
spectrum characteristic of dityrosine (retention time after 10 min) (Fig 5.6). Therefore 
cross-linking through dityrosine appears to be responsible for the aggregation of 
HMWK after exposure to the oxidizing agent. The stability of HMWK aggregates 
was also characterized by reduction with 2-mercaptoethanol (reducing agent). There 
was a considerable decrease in aggregated products on reduction confirming the 
involvement of disulphide linkages. 
LOSS OF SECONDARY STRUCTURE AND UNFOLDING OF THE 
PROTEINS 
Changes in the secondary structure of the inhibitor were followed by 
measuring the far-UV CD spectrum (200-250 nm). Photodynamic modifications 
significantly altered the far-UV CD spectra of native HMWK. Analysis of the data for 
increasing time periods of incubation with oxidizing agent shows that the ellipticities 
at 209 nm, which reflects the a helical content of a protein (Chen et al., 1975), leads 
to a significant loss of a helicity in the protein. Simuitancoush' the posili\'c extrcmum 
at 200 nm is also considerably reduced and the peak failed to roach positive vahics 
after 60 min of incubation (Fig. 5.7). The changcs ofellipticit) at 200 nm and 209 nm 
is usually supposed to be associated with the change of secondar>- structure of the 
polypeptide chain (Chen et al., 1975) i.e. they reflect the change of conformation of 
the entire molecule. UV absorption spectra of riboflavin treated HMWK relative to 
untreated protein suffered a blue shift to 275 nm with an increase in energy suggesting 
a change in the tryptophan environment (Fig. 5.8). 
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Figure 5.6 HPLC of riboflavin treated HMWK following incubation with 
trypsin 
HMWK (500 nmoles) treated with riboflavin were incubated with proteolytic 
enzyme Trypsin (10 |ig/ml) for 24 hours before undergoing PCA precipitation 
and NaOH neutralization as described under Methods section. The results 
shown in both trace A and trace B are representative chromalograms from 
multiple experimental incubations and HPLC separations. Trace A, shows a 
cliromatogram obtained by trypsin digestion and PCA precipitation of 
oxidized HMWK.Peak 2 corresponds to dityrosine which was confirmed by 
elution of dityrosine standard and fluorescence spectrum ?tex=284 nm; 
410 nm Trace B Dityrosine standard. 
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Figure 5.7 Far UV-CI) spectrum of HMWK treated with riboflavin at 
different time intervals 
Far UV-CD spectrum of HMWK (0.1 mg/nil) exposed to different time 
intervals of riboflavin incubation. The time intervals for curves were ( — ) 0, 
(...) 10, (—-) 20, ( _ ) 30. ( ) 40 and ( - ) 60 min respectively. 
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Figure 5.8 UV absorption spectra of untreated and riboflavin treated 
HMWK 
The UV spectra of native and treated HMWK were taken as described in the 
materials and methods. Trace 1 is the absorption spectrum of untreated 
HMWK, trace 2 corresponds to absorption spectrum of riboflavin treated 
HMWK. 
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DISCUSSION 
Radical mediated protein oxidation has been studied throughout the century. 
Dakin (1906, 1908) first published detailed chemical studies of the oxidation of 
leucine and another amino acids by Fenton system, protein aggregation and 
(apparently) fragmentation were then detected by other workers. 
Dakin (1908) elucidated much of the chemistry of the products of protein 
oxidation. He detected the formation of carbonyls from amino acids, such as the oxo 
acids and aldehydes with the same or one less carbon atom than the parent amino acid 
e.g. glycine giving rise to glyoxal and glyoxylic acid, formaldehyde and formic acid; 
alanine giving rise to acetaldehyde and acetic acid. Kopolodova and coworkers (1963) 
characterized the oxidation of aliphatic amino acids, which were then fully defined for 
valine and leucine resulting in the formation of valine and leucine hydroperoxide and 
hydroxides (Dean et al., 1996). Oxidation of aromatic residues, phenylalanine, 
tryptophan and histidine result in the formation of ortho and meta tyrosine (Huggins 
et al., 1993) 5-hydroxytryptophan, 7-hydroxytryptophan (Guptasarma et a!., 1992; 
Armstrong and Swallow, 1969; Maskos et al., 1992) and 2-oxohistidine (Uchida and 
Kawakishi, 1993) respectively. Oxidation of tyrosine residues form phenoxyl radicals, 
which are subsequently converted to dityrosine if there are vicinal tyrosyl radicals 
(Heinecke et al., 1993; Huggins et al., 1993). Conversion of -SH to disulphides and 
other oxidized species (e.g.oxyacids) is one of the earliest observable events during 
the radical mediated oxidation of proteins. Schiff bases which are short lived species 
are also formed by the reaction of carbonyl groups with amines during exposure of 
proteins to lipid derived aldehydes like 4 hydorxynonenal and autoxidizing aldehydes 
(Kautiainen, 1992). 
Much of the knowledge concerning the mechanism of ROS damage to 
proteinS comes from early studies in which proteins were exposed to ionizing 
radiations (Garrison, 1968; Swallow, 1960; Garrison et al., 1962; Garrison and 
Weeks, 1962; Liebster and Kopoldova, 1966; Makada and Garrison, 1972; Schuessler 
and Hergt, 1980; Schuessler and Schilling, 1984). Exposure of proteins to radiolysis 
leads to the production of long-lived protein hydroperoxide adducts (Garrison, 1968; 
Swallow, 1960; Simpson et al., 1992) and to structural perturbations other than 
fragmentation and aggregation. Among other changes radiolysis leads to change in 
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hydrophobicity (Schuessler and Schilling, 1984; Davies, 1987a, 1987 b); a decrease in 
the isoelectric point, due to a loss of basic amino acid residues namely lysine, arginine 
and histidine (Davies and Delsignore, 1987; Schuessler and Schilling, 1984; Davies, 
1987 a); or to the production of more acetic residues associated with the conversion of 
histidine, proline and cysteine residues to aspartic, glutamic and cysteic acid 
respectively (Amici et al., 1989). It may also result in an increase in sensitivity to 
proteolytic degradation; to alteration in the circular dichroism (CD) spectrum, or 
changes in viscosity (Baron and Finkelstein, 1952; Bellamy et al., 1956); and in case 
of enzymes, to loss of catalytic activity (Garrison, 1968; Swallow, 1960; Aldrich and 
Cundall, 1969; Schuessler and Hergt, 1980). 
The primary source of free radical in most oxygenated biological system is the 
superoxide radical, which is in equilibrium with its protonated form, the 
hydroperoxide radical. The major sources of these free radicals are modest leakage 
from the electron transport chain of mitochondria, chloroplasts and endoplasmic 
reticulum (Dean et al., 1997). When neutrophils are activated, a series of metabolic 
activities are stimulated (Hatherill et al., 1991) collectively these changes are termed 
as respiratory burst. The respiratory burst is associated with increase oxygen uptake, 
NADPH production from hexose monophosphate shunt and reduction of oxygen 
forming superoxide radical and hydrogen peroxide. The intermediate products, 
superoxide, hydroxyl radical and hydrogen peroxide of this pathway are reactive in 
biological systems to varying degree. The formation of the superoxide radical results 
from a membrane-bound NADPH oxidase during respiratory burst when granulocytes 
or macrophages are activated to particular stimuli (Tsou and Yang, 1996). Due to the 
activation of the membrane-bound NADPH oxidase, electrons are transferred from 
cytosolic NADPH to extracellular oxygen producing the superoxide radical. From this 
one electron-reduccd form of oxygen, other ROS such as hydrogen peroxide, singlet 
oxygen and hydroxyl radical are formed from subsequent reactions, partly catalyzed 
by metal ions (Wang ct al., 1993). The hydroxyl radical is postulated to be formed 
from the modified modified Haber-Weiss or Fenton reaction a transition metal serves 
as a reducing agent (Klebanoff, 1980). 
O2 + Fe'^ • O2+ Fe^^ 
Fe^^ + H2O2 • Fe^^+OH"+OH 
Several proteinase inhibitors are inactivated by reactive oxygen species 
released by activated neutrophils (Johnson and Travis, 1979; Lawrence and Loskutoff, 
1986; Stieff et al., 1988). Neutrophils create a microenvironment in which neutrophil 
proteinases are able to cause tissue destruction despite the presence of proteinase 
inhibitors (Henson and Johnston, 1987; Campbell et al., 1982; Weiss, 1989; Wong 
and Travis, 1980). a2-macroglobulin one of the proteinase inhibitors is inactivated by 
ROS generated by activated neutrophils (Reddy et al., 1989). In vitro studies show 
that ai-proteinase inhibitor (aj-PI), a plasma protein on oxidation by N-Choloro 
succinimide that specifically oxidizes methionine residues to methioriyl sulfoxide 
(Savige and Fontana, 1977) inactivates this inhibitor towards elastolytic proteinases 
(Jolinson and Travis, 1979). Similarly Kozik et al (1998) demonstrated that human 
HMWK are damaged by oxidative modification of methionine residues in kinin 
fragment of HMWK, resulting in decrease of kinin generation. Chemical modification 
of the histidine residues in HMWK results in over 90% loss of procoagulent activity. 
Modification of tryptophan, aspartic acid and glutamine residues confirmed, their 
involvement in protein binding (Retzois et al., 1987). 
In the present study HMWK from sheep plasma, which shows resemblance to 
human H M W K in several properties, was selected, to study the functional state of this 
inhibitor on exposure to ROS. The above results show that sheep plasma HMWK is 
susceptible to reactive oxygen species generated by photosensitized riboflavin, which 
mimics biological exposure to oxygen radicals (Joshi, 1985; Tsai et al., 1985). 
HMWK susceptibility to oxidation was measured by its ability to be used as 
proteinase inhibitor after photodynamic modification. Photodynamic action of various 
sensitizers has long been applied to delineate structural and functional properties of 
large number of enzymes and other biologically active proteins. (Hopkins and Spikes, 
1969; Spikes, 1977). Incubation of HMWK with increasing concentration of 
riboflavin (Table 3.0) and varying time periods of incubation with riboflaxin 
inactivates its antiproteinase activity towards papain (Fig. 5.0) owing to destruction of 
active site tryptophan residues. Tryptophan fluorescence was completely lost and a 
decrease in fluorescence intensity was observed in HMWK on incubation with 
riboflavin (Fig. 5.4). Loss of tryptophan fluorescence results from both tryptophan 
oxidation and conformational change. There was clear protection of tryptophan 
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residues from oxidation, observed by retention of native tryptophan fluorescence in 
the presence of various scavengers and antioxidants (Table 3.2). 
It was of interest in the present study to learn whether singlet 'O2 is implicated 
in the cross linking reaction. The characterization of patterns of protein oxidation 
elicited by various forms of ROS is fiindamental to the development of diagnostic 
tests to identify the kind of ROS that are implicated in the etiology and progression of 
various pathological disorders. The utilization of enhancers, scavengers and 
quenchers is the method most often used to investigate the role of ROS in 
photosensitization reaction (Rywkin et al., 1992). One approach to this was to carry 
out reaction in D2O (known to increase the life span of singlet 'O2) and H2O media 
and compare the degree of cross-linking and inactivation in these media. It was found 
that the rate of HMWK photoinactivation and aggregation was enhanced in D2O (Fig 
5.0 and Fig 5.2). Aggregated products were formed within 5 min of incubation and 
75%±2.5 of inhibitory activity was lost towards papain within 10 min of incubation 
(Fig 5.0) whereas HMWK still retained 70%±2.9 inhibitory activity when the 
reaction was carried out in H2O (Fig 5.0). Sodium azide and potassium iodide that are 
known to quench singlet 'O2 and flavin triplet state respectively (Dahl and 
Richardson, 1980) were also used. They resulted in protection of inhibitory activity 
and no aggregated products were formed (Fig 5.3 A Table 3.1). Previous studies had 
shown that singlet 'O2 and flavin triplet state are involved in polymerization of 
proteins (Girrotti, 1978; 1979; Goosey, 1980). Effect of mannitol and thiourea (known 
to eliminate hydroxyl radicals) on photoinactivation were less pronounced as 
compared to sodium azide and potassium iodide (Table 3.1). The above results thus 
confirm that the photodynamic modification of riboflavin on HMWK proceeds mainly 
via singlet 'O2. 
Various antioxidants are present in aqueous phase of plasma, which include 
ceruloplasmin, albumin, ascorbic acid, transferrin, haptoglobin and hemopoxin 
(Halliwell and Gutteridge, 1990). In plasma, ascorbic acid is one of the most 
important antioxidant, sparing other antioxidants by forming the first line of defense 
against free radicals and peroxides that are generated during cellular metabolism (Frei 
et al., 1989; Halliwell and Gutteridge, 1990; Kaneko et al., 1993). Ascorbic acid 
circulates in plasma at concentrations of 50-200 fxM in unsuppleriiented individuals 
(Halliwell and Gutteridge, 1990) and these concentrations can almost be doubled with 
oral supplements (Saubberlich, 1975; Levine et al., 1995). Plasma ascorbate 
concentrations are maintained by intestinal absorption (Stevenson and Brush, 1969; 
Mellors et al., 1977) renal reabsorption (Toggenburger et al., 1981; Martin et al., 
1983; Rose, 1988), slow release from circulating erthrocytes (Mendiratta et al., 1998) 
and possibly by secretion from the liver (Upston et al., 1999). Most tissues avidly take 
up and retain ascorbate in its reduced form from plasma and interstitial fluids. 
Ascorbic acid scavenges, HOi, water-soluble peroxyl (RO2) radicals, singlet oxygen 
in aqueous solution and is also powerful scavenger of HOCl (Halliwell and 
Gutteridge, 1990). Ascorbic acid protects ai-proteinase inhibitor against inactivation 
by HOCl produced by myeloperoxidase (Halliwell et al., 1987) Sheep HMWK treated 
with riboflavin in presence of ascorbic acid resulted in complete retention of 
inhibitory activity towards papain (Table 3.1) and also protection of tryptophan 
residues from oxidation. (Table 3.2). Ascorbic acid is also used in large doses for 
certain diseases (Halliwell, 1990; Frei, 1989). In sickle cell disease (Jain and 
Williams, 1985) rheumatoid arthritis (RA) (Lunce and Blake, 1981) adult distress 
syndrome (ARDS) and iron overload diseases (Neinhuis, 1981), ascorbic acid 
concentrations in body fluid are markedly subnormal. In RA and ARDS this happens 
because of the rapid uptake and oxidation of ascorbate by activated neutrophils 
(Winterbourn and Vissers, 1983; Washko et al., 1989). 
Uric acid an end product of purine metabolism, functions as an antioxidant in 
vivo. The normal physiological concentration of uric acid in human plasma is 0.2-0.35 
mM (Davies et al., 1986 and 1990). Uric acid can act as an antioxidant both by 
binding iron and copper ions in forms so that the rate of free radical reactions is 
decreased directly by scavenging oxidizing species such as singlet'Oi, hydroxyl 
radical, HOCl, peroxyl radical (Halliwell and Gutteridge, 1990). However in the 
present study uric acid was neither able to prevent aggregation (Fig. 5.3), nor retained 
the antiproteinase inhibitory activity of HMWK (Table 3.1). It was also not able to 
protcct the tr)ptophan residues from oxidation (Table 3.2). This is attributed to the 
fact that uric acid with certain oxidizing species such as .OH or peroxyl radicals can 
generate uric acid radicals that are themselves capable of doing biological damage by 
inactivating certain enzymes e.g. a]-antiproteinase, that is inactivated by oxidizing 
agent in presence of uric acid (Arouma and Halliwell, 1988). Increased uric acid 
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concentrations have also been observed in body fluids under certain diseased 
conditions such as hyperuricemia, gout and arthritis (Grootveld et al., 1987). 
The formation of protein aggregates during incubation of HMWK with 
riboflavin could be due to the formation of intermolecular disulphide bridges, 
dityrosine cross linkages, or due to exposure of hydrophobic regions on the protein 
following the perturbation of tryptophan residues. Reduction of treated HMWK by 2-
mercaptoethanol resulted in considerable decrease of protein aggregates on SDS-
PAGE indicating that intermolecular disulphide bonds are involved in aggregate 
formation. Our data indicate that dityrosine is formed during exposure of HMWK to 
oxidizing agent, observed by increase in emission at 410-420 nm when excited at 325 
nm (Fig 5.5). The scheme for dityrosine formation involves one electron oxidation of 
L-tyrosine by ferricyanide, which generates the long, lived tyrosyl radical (Sealy et 
al., 1985). Two tyrosyl radicals productively interact, and the major product is O, O 
dityrosine (Musso, 1963) an intensely fluorescent compound ( Joschek and Miller, 
1966). 
OH 
H^ 
R 
O:-
R 
e-
0" 
R 
O 
0 
R 
R 
Oil 
OH 
R R 
O O 
R R 
(A) 
+ Otherproducts (B) 
Dityrosine formation takes place during exposure of purified proteins to oxidizing 
agents in vitro and also in intact red blood cells. Formation of ditsrosinc has been 
detected only in a few proteins such as fatty acid free bovine serum albumin, (Davies. 
1986a) human manganese superoxide dismutase, epidermal growth factor (Dean et 
al., 1997), sperm whale myoglobin (Tew and Montellano, 1988) and a synuclein 
(Souza et a l , 2000). Dityrosine is more likely formed between two protein molecules 
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(intermolecular bonding) rather than within a single protein (intramolecular bonding). 
In case of spemi whale metmyoglobin on reaction with H2O2 results in dimerization 
of the hemoprotein. Dimerization was found to be largely due to dityrosine formation. 
Dityrosine cross links were found to be forged between Tyr 151 of one chain and Tyr 
103 of the other chain. Computer graphics docking experiments suggested Tyr 151 of 
one chain has direct access to both Tyr 103 and Tyr 151 of the second chain .The 
formation of Tyr 151/Tyr 103 covalent bond rather than Tyr 151/Tyr 151 crosslinks 
are governed by charge interactions that disfavor cross linking of the Tyr 151 residues 
(Tew and Monteilano, 1988). 
Guptasarma et al (1992) had cautioned that results based on fluorescence 
detection for dityrosine formation are suspect, because the oxidation of tryptophan 
residues in proteins by hydroxyl radicals leads to the formation of N-
formylkynurenine, which also exhibits strong fluorescence at 400-450 nm when 
excited at 325 nm. This point is underscored by the demonstration that oxidation of 
Trp residues in mellitin, which contains no tyrosine, leads to an increase in 
fluorescence at 400-450 nm (excitation at 325 nm), but this increase is not 
accompanied by dimerization of the molecule. Dityrosine generated remains in the 
intact protein unless released by the action of proteolytic enzymes (Guilivi and 
Davies, 1993) and the levels of dityrosine generated are not also high. However the 
sensitivity of flourimetric detection method coupled with specificity of HPLC 
separation makes dityrosine measurement a relatively simple and powerful procedure 
for identification of free radical modification. In order to confirm the formation of 
dityrosine cross linkages in oxidized HMWK, the inhibitor was treated with PCA and 
trypsin. The peptides released were analyzed by HPLC attached to a fluorescence 
detector. Peptides with characteristic fluorescence of dityrosine were identified in 
oxidized HMWK (Fig 5.6). 
Very little protein unfolding occurs in most of the examples of protein 
inactivation (Dean et al., 1997). Photo incubation of HMWK profoundly alters the far 
UV CD spectrum. The CD analysis of treated protein indicated that with increasing 
time periods of incubation there is decrease in the amount of a-helix. Simultaneously 
there is a marked decrease in the size of the peak at 200 nm indicating a decrease in 
the p sheet content of the protein (Fig. 5.7). Furthermore the blue shift observed in the 
UV absorption spectra (Fig. 5.8), is generally considered to be a modification near the 
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tryptophan environment, which Ues to be in the interior of the protein (Edwin and 
Jagannadham, 2000). 
The above findings assume significance in view of the fact that HMWK could 
be damaged by reactive oxygen species in vivo, which is evident, by the experimental 
investigations in vitro. Since HMWK has been found in oxidized form in both human 
rheumatoid synovial fluid (Wong and Travis, 1980) and in lung washings from 
cigarette smokers (Gadek et al., 1979). Therefore loss of antiproteinase activity of 
HMWK on exposure to reactive oxygen species suggests that there can be an 
imbalance of proteinase-antiproteinase activity during certain inflammatory diseases, 
such as gout and arthritis, which may unleash a whole cascade of tissue destruction. 
The result of these experiments also allows reaching to certain conclusion concerning 
the inhibitory site of HMWK. It clearly shows that tryptophan residues are located in 
or near the proteinase-binding site (Baba et al., 2004). Earlier it had been reported that 
in chicken cystatin Trp 104 is directly or indirectly involved in the interaction with 
proteinase (Nycander and Bjork, 1990). The position of tyrosine residues forming 
dityrosine cross linkages, and tryptophan residue in HMWK involved in interaction 
with the proteinase inhibitor needs to be further investigated. 
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RESULTS 
Guanidinium hydrochloride (GdnHCl) induced changes in the structural and 
functional properties of HMWK have been investigated. Time dependent changes in 
structural parameters and inhibitory activity of HMWK at increasing (GdnHCl) 
concentrations (0-6 M) were monitored to standardize the incubation time required for 
achieving equilibrium under these conditions. Under all the conditions studied, the 
changes occurred within maximum of 1 hour with no further alteration upto 12 hours. 
These observations demonstrated that an incubation time of 1 hour was sufficient for 
achieving equilibrium under any condition of denaturant studied. 
CHANGE IN THE INHIBITORY ACTIVITY 
HMWK is a multifunctional protein involved in blood coagulation cascade, 
kinin formation and cysteine proteinase inhibitory activity. Conformational changes 
during various treatments reflect subtle readjustments that allow very small 
conformational variations in the structure of the inhibitor to be detected. Therefore 
changes in the inhibitory activity were taken as a probe to study the changes in 
HMWK structure. The effect of GdnHCl concentrations on the inhibitory activity of 
HMWK is shown in Fig. 6.0. The results show that at low GdnHCl concentrations 
less than 1.0 M GdnHCl, the inhibitory activity towards papain is completely lost, 
with an estimated midpoint concentration at 0.5 M GdnHCl. However at less than 0.2 
M GdnHCl concentration, HMWK retained more inhibitory activity (160%). These 
results suggest that changes at the inhibitory sites of HMWK by low concentrations of 
GdnHCl bring about the temporary activation of HMWK. It had been earlier reported 
for some enzymes such as adenylate kinase, chicken liver dihydrofolate reductase and 
lipocalin type prostaglandin 1) synthase fatty acid synthase that low concentrations of 
dcnaturants results in activation of these proteins. Activation of these enzymes by low 
concentrations of urea and GdnHCl is accompanied by a conformational change at the 
active site, and by changes in the secondary structure (Zhang et al., 1997; Fan et a l , 
1995; Fan et al., 1996; Inui el al., 1999). 
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CONFORMATIONAL CHANGES DURING DENATURATION 
Effect of GdnHCl on Tryptophan Fluorescence Spectrum of HMWK 
Optical spectroscopic studies on HMWK in presence of increasing GdnHCl 
concentrations were performed to study the effect of denaturant on the structural 
properties of HMWK. The spectral parameters of tryptophan fluorescence emission 
such as position, shape and intensity are dependent on the electronic and dynamic 
properties of the chromophore environment hence; steady-state tryptophan 
fluorescence has been extensively used to obtain information on the structural and 
functional properties of the protein. The modification of the microenvironment of 
tryptophan residues of HMWK due to denaturants was monitored by studying 
changes in the intensity and wavelength of emission maxima (^max) as a function of 
denaturants. Native HMWK has emission maxima (^^max) at 330 nm when excited at 
280 nm. The buried tryptophan residues in the folded protein show the fluorescence 
emission A,max at 330-340 nm (Lakowicz, 1983) hence in native HMWK the 
tryptophan moieties are buried in hydrophobic core of the protein. At intermediate 
GdnHCl concentrations, the denaturation behavior of HMWK monitored by 
fluorescence is complex as shown by the fluorescence emission spectrum (Fig. 6.1), 
which was not intermediate between the native HMWK and that in 6 M GdnHCl. 
From 0-2 M GdnHCl the fluorescence intensity decreases by about 37%. The 
quenching of tryptophan fluorescence of native HMWK may have occurred due to 
compaction of the native conformation of the inhibitor. Akhter et al (2002) reported 
that in case of glucose oxidase, which is a homodimer, quenching of tryptophan 
fluorescence during denaturation occurs, due to compaction of native conformation of 
the enzyme. The shift in the emission maximum of HMWK on denaturation has two 
distinct steps. In the first step which was completed at 2.5 M GdnHCl the emission 
was shifted to 335 nm. In the second step which was between 3-5 M GdnHCl the 
emission maxima was shifted to 345 nm. In the concentration range 3-5 M GdnHCl, 
both the intensity and wavelength of tryptophan emission remained nearly constant 
(Fig. 6.2) Normally exposed tryptophan residues in the unfolded protein show 
emission maxima between 345 nm and 350 nm (Lakowicz, 1983). Hence treatment of 
HMWK with higher concentrations of GdnHCl results in exposure of the buried 
tryptophan moieties present in native HMWK to the solvent, such a situation happens 
only when the denaturant induces unfolding of proteins. 
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In order to ascertain to which extent the secondary structure is affected by the 
denaturant, circular dichroism spectra were measured in the peptide region, and the 
intensity at 222 nm was reported as a function of denaturant concentration. For low 
GdnHCl concentration (0.1-0.2 M) the secondary structure increased slightly (Fig. 
6.3). Upon treatment of HMWK with increasing concentration of GdnHCl, the far 
UV-CD spectrum shows a decrease in intensity at 222 nm, at least in two stages, from 
the native state to an intermediate state (25% decrease in ellipticity value) largely 
populated at 3.0 M GdnHCl.Between GdnHCl concentrations of 3.5-5.0 M there was 
a large gradual decrease in ellipticity at 222 nm to almost complete loss of signal. The 
midpoint concentrations of the two phases were 1.5 M and 4.0 M, respectively (Fig. 
6.4). These observations suggest that treatment of HMWK with higher GdnHCl 
concentration results in complete unfolding of the enzyme. 
Comparison of Inactivation and Conformational Changes of HMWK 
At low GdnHCl concentration (1 M) the inhibitory activity of HMWK was 
completely lost, while no significant structural changes were observed. The loss of 
inhibitory activity at low concentrations of GdnHCl may be due to small distance 
changes between the component inhibitory site or to the direct effect on the inhibitory 
site. The data at different GdnHCl concentrations indicates that the shape of the far 
UV-CD spectra (Fig. 6.4) and inhibitory activity transitions (Fig. 6.1), that at 1 M 
GdnHCl there is no inhibitory activity however elements of helical secondary 
structure arc present. Therefore inhibitory site of multifunctional HMWK displays 
more conformational flexibility than the HMWK molecule as a whole, so it is more 
easily affected by GdnHCl . 
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DISCUSSION 
Guanidine hydrochloride and urea are the most commonly used chemical 
denaturants for protein denaturation. The conformational stability of multimeric 
proteins has generally been studied in the presence of these denatuarnts. Such studies 
have helped in understanding the rationale for the formation of oligomers and assess 
the strength of the tertiary and quarternary level interaction in protein biogenesis. 
Equilibrium unfolding studies have so far provided considerable information on stable 
intermediate states in small monomeric proteins. Unfolding transitions of multimeric 
proteins has been useful in establishing the hierarchy of events that occur during 
denaturation (Jaenicke, 1987B). 
HMWK is a multifunctional protein, which has six domains and each 
individual domain, has a separate function, kinetically and structurally independent of 
its neighboring domain functions (Sueyoshi et al., 1988). HMWK purified from sheep 
plasma is a homodimer, in which a single disulphide bond holds the two polypeptides 
together. HMWK being a large protein molecule, so it may easily misfold and may 
not easily refold as well. The inhibitor appears to be an interesting experimental 
model to investigate the protein folding of dimeric proteins held by disulphide 
linkage. 
The equilibrium transition curves for the unfolding of HMWK by GdnHCl for 
different parameters like i) inhibitory activity ii) relative fluorescence emission 
intensity and iii) the ellipticity at 222 nm could not be superimposed. During GdnHCl 
unfolding, instantaneous activation of the inhibitory activity at very low GdnHCl 
concentrations (0.1-0.2 M) was observed (Fig.6.0). To explain the exact mechanism 
from the approaches used in the present study is difficult, since it was a temporary 
efTect. Activation may have been induced by increasing the flexibility of the protein 
conformation by secondary structural changes. As shown in Fig 6.3 the far UV-CD 
spectra had abnormal slight increase of a-helical structure at low GdnHCl solutions. 
These results give some clue lo explain the mechanism. Complete inactivation of the 
inhibitory activity of HMWK occurs below 1.0 M GdnHCl (Fig. 6.0), while unfolding 
results only at GdnHCl concentration above 3 M. At GdnHCl concentration of 0.9-1.0 
M the inhibitor is predominantly an inactive dimer with no great loss of secondary 
structure (Fig. 6.4). Interaction between papain and kininogen is hydrophobic 
(Sueyoshi et al., 1988). The computer-generated model of human HMWK domains. 
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DII, Dili and cystatin had indicated that the regions that inhibit papain are first 12 
residues of the NHi terminus (peptide 146-157) and QVAAG region (185-198) 
(Fig. 1.3) (Bradford et al., 1993). The local fragility of HMWK indicates a flexibility 
of the binding sites probably necessary for a productive orientation of HMWK on the 
proteinase (Fig.6.0) It is generally thought that transitions at very low denaturant 
concentrations imply less stability of flexible local domain (S), held together by 
weaker forces, rather than distinct structural intermediates of the molecule as a whole 
(Couthon et al., 1995). Earlier Tsou (1986 andl987) in his detailed studies on 
denaturation of creatinine kinase and other enzymes, suggested that the 'active sites 
are usually situated in a limited region of the enzyme molecule that is more fragile to 
denaturants than the protein molecule as a whole'. The above results show that Tsou's 
suggestion that the enzyme active site is more flexible can also be applicable to 
cysteine proteinase inhibitors. Alternatively the local effects of GdnHCl that bring 
about stimulation dominate at lower GdnHCl concentration (<0.2 M) and denaturing 
properties of GdnHCl dominate at concentrations above 1.0 M. Thus the inhibitory 
profile of HMWK in GdnHCl is a result of two effects stimulatory and denaturing 
effect of GdnHCl. 
Intrinsic tryptophan fluorescence was employed to follow the tertiary 
structural changes occurring within HMWK during denaturation. The changes in the 
fluorescence emission spectrum of HMWK after denaturation in increasing 
concentration of GdnHCl occurred in three stages. Although the fluorescence 
emission intensity experienced complex changes the emission always red shifted 
abo% e 1.0 M GdnHCl (Fig. 6.2). The decrease of fluorescence intensity observed upto 
2.0 M GdnHCl may be caused by a tertiary structural rearrangement involving a 
tri ptophan residue (s) in dimer HMWK or because of the increased mobility of the 
local on\ ironment of the tryptophan. A combination of these factors may also be 
responsible. From 2.0 to 3.0 M GdnHCl the fluorescence intensity increased by 30% 
and the spcctral maximum shifts to longer wavelength consistent with unfolding (Fig. 
6.1). In the range of 3.0-5.0 M GdnllCl both the intensity and the wavelength 
maximum of emission remain constant, consistent with the ensemble of 
interconverting conformations (Fig. 6.1 and Fig. 6.2). 
The circular dichroism spectrum of native HMWK exhibiting a 222 nm 
minimum in the far UV region is due to the a-helical structure of the protein (Fig. 
1 3 1 
6.3). Upon treatment of HMWK with 5 M GdnHCK the far-UV CD spectrum shows a 
large decrease in intensity at 222 nm due to loss of the a- helical content (Fig. 6.4). 
Generally unfolding studies performed on oligomeric proteins had indicated 
that their denaturation was either two state or three state transition depending on the 
extent of stabilization of subunits of quaternary structure-i.e. whether the structure of 
the subunit was stabilized by intersubunit interaction. Most of the unfolding studies of 
oligomeric proteins, which were done, either do not have any intersubunit disulphide 
bonds or the experiments were done under reducing conditions. Unfolding studies of 
red kidney bean purple acid phosphatase a homodimer held together by a single 
disulphide linkage showed atleast three intermediates during denaturation (Cashikar 
and Rao, 1996). 
In the present unfolding study of HMWK, the unfolding curves for different 
parameters like inhibitor}' activity; exposure of tryptophans and loss in secondary 
structure could not be superimposed. Non-coincidence of denaturation profiles 
observed by different techniques suggests the presence of intermediates in the process 
of unfolding. In order to estimate the conformational stability, and the various 
intermediates formed further experiments need to be done. 
In the present study several findings during physicochemical characterization 
of kininogens from sheep plasma, shed some light on the mechanisms involved in 
conformational and structural changes that kininogens can undergo on exposure to 
ROS. These studies showed that HMWK could be damaged by ROS in vitro and this 
can be one of the mechanism of inactivation of HMWK in vivo leading to proteinasc-
antiproteinase imbalance, which is one of the leading cause of several diseases. It has 
also been suggested that intermediates are formed during the unfolding of HMWK on 
incubation with varying concentrations of GdnHCl. 
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Riboflavin sensitized photodynamic modifications of high 
molecular weight Kininogen (HMWK) isolated from sheep 
(Avis-arias) plasma leads to inactivation of antiproteinase 
activity and formation of aggregated products. A continued 
disappearance of the inhibitory activity towards papain and 
formation of high molecular weight adducts was observed 
with increasing concentration of riboflavin and varying time 
periods of incubation reaching a maximum value of over 85% 
(loss in activity). Aggregates resisted dissociation upon 
heating at 1(X)°C in 1% SDS. Aggregation and photoinactiva-
tion of HMWK was promoted by the substitution of H2O for 
deuterium oxide (D2O), which is known to prolong the life 
span of singlet oxygen, and suppressed by sodium azide a 
known singlet oxygen quencher. Mannitol and thiourea 
(hydroxyl radical scavenger) did not protect the anti-
proteinase activity of HMWK. Treatment with reducing 
agent resulted in decrease of the aggregated products 
suggesting the possible involvement of disulfide linkages in 
protein crosslinking. Tryptophan fluorescence was comple-
tely lost and significant production of dityrosine was 
detected in photoinactivated HMWK aggregates. Changes 
in the far Ultra violet circular dichroism (u.v.c.d.) spectrum 
of HMWK was indicative of loss of secondary structure. 
Analysis of modifications induced in HMWK by riboflavin 
reveals that the processes proceed via a singlet oxygen 
mediated pathway. It is concluded that the susceptibility of 
HMWK to oxidation may arise from oxidative modifications 
by reactive oxygen species generated in plasma. 
Keyxoords: Kininogen; Cysteine proteinase inhibitor; Aggregation; 
Inactivation; Singlet oxygen 
I N T R O D U C T I O N 
Kininogens are multifunctional glycoproteins pre-
sent in plasma and secretions of mammalian 
s p e c i e s . ' ^ I n human and bovine, two forms of 
kininogens {H-kininogen, high molecular weight 
kininogen or HMWK and L-kininogen, low molecular 
weight kininogen or LMWK) and several other 
species are present.'^'^' HMWK is composed of a N 
terminal heavy chain. The heavy chain and kinin 
segment of HMWK can be subdivided into four 
domains, the cystatin like domains Dl, D2 and D3, 
and the kinin segment D4. The light chain of HMWK 
can be subdivided into D5 and Dl does not 
inhibit proteases. D2 and D3 contain the conserved 
pentapeptide QVVAG, responsible for proteinase 
inhibition, which is also found in class II cystatin and 
stefins.'^"^' The procoagulent activity of HMWK 
resides exclusively in D5 and 
Functional changes have f requent ly been 
suggested to occur in proteins with oxidation-
sensitive amino acid residues like cysteine, meth-
ionine, histidine, and tryptophan located at or near 
the sites of specific interaction in prote ins . ' " ' 
Oxidative modification of HMWK markedly reduces 
kinin production when exposed to plasma or tissue 
kallikreins.'^^' Anastassios et fl/.'^^ reported that 
chemical modification of the light chain of HMWK 
affects the procoagulent activity, surface binding and 
the binding of protein with zinc indicating that 
histidine imidazoles are involved in surface and zinc 
binding, free carboxyl and tryptophan aromatic side 
groups participate in protein binding. Chemical 
modification of Trp-104 markedly affects the binding 
of chicken cystatin to papain. ' ' Chicken cystatin 
forms a tight equimolar complex (kd ~ 60 fm) with 
papain, blocking the active site of the enzyme.'^^' 
From computer docking experiments three regions 
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of the chicken cystatin are suggested to interact with 
the enzyme, namely the segment of the chain around 
Gin-Leu-Val-Ser-Gly sequence at residues 53-57, 
and the loop around Trp-104 of the inhibitor.'^^' 
Flavins are known to photooxidize amino acids 
and also effect the conformation of proteins.'^^"^°' 
Riboflavin is known to generate singlet oxygen, 
hydroxyl radical and flavin triplet state on photo-
illumination.'^^' The present work was carried out 
to examine riboflavin mediated photodynamic 
modifications of HMWK to elucidate the location 
of the reactive site, types of ROS involved and 
various structural changes associated with them. 
Our studies indicate that the oxidation of trypto-
phan residues of HMWK inactivate this inhibitor 
towards papain. Spectroscopic characterization of 
photoinactivated HMWK aggregates have shown 
marked difference relative to native protein. Singlet 
oxygen and flavin triplet state were found to be 
involved in these modifications by the use of 
various scavengers and enhancer. The present 
findings indicate dityrosine formation in HMWK 
on exposure to riboflavin. We present a compre-
hensive characterization of these changes by 
various spectroscopic methods. 
Reaction of Photosensitized Riboflavin with 
H M W K 
HMWK (500-600 nmoles) was photoilluminated 
with increasing concentration of riboflavin 
(5-40 ^iM) in a final volume of 1000 |xl at room 
temperature (28-30°C). Riboflavin was freshly 
prepared at 2 m M concentration in 50 mM sodium 
phosphate buffer pH 7.5. HMWK was photoillumi-
nated for different time intervals (0-60 min) with 
40 jjlM riboflavin in a final reaction volume 1000 jjlI at 
room temperature. Further, HMWK was incubated 
with riboflavin for different time intervals in which 
H2O was replaced by D2O. The light incubations 
were done by setting tubes at a distance of 1 cm from 
40 W cool fluorescent lamp. The light intensity was 
0.768 milliwatt at a distance of 1cm measured by a 
Model 351A-Powermeter. 
Riboflavin-HMWK Interaction in the Presence of 
Scavengers and Antioxidants 
HMWK (500-600nmoles) was incubated with 
40|xM riboflavin for I h along with sodium azide, 
potassium iodide, thiourea, mannitol, uric acid and 
ascorbic acid. 
M A T E R I A L S A N D M E T H O D S 
Papain, Trypsin, Phenylmethylsulphonylflouride 
(PMSF), Ethylene diamine-tetraacetic acid (EDTA), 
Casein, Uric acid. Thiourea, Mannitol, Sodium azide. 
Ascorbic acid. Potassium iodide. Riboflavin, Casein, 
Sephacryl-S300HR, D2O were from Sigma Chemical 
Company (St. Loius, MO). High molecular weight 
protein markers were from Genie India Limited. All 
the other reagents were of highest purity commer-
cially available. 
Purification of H M W K 
HMWK was purified from sheep plasma. Sheep 
blood was routinely collected at slaughter (within 
few minutes after the animal were killed) in plastic 
bottles containing 1/10 volume of acid citrate 
dextrose containing I m M PMSF/STl (50mg/l of 
blood). HMWK was purified in high yield by a 
simple two-step procedure. Protein precipitated 
between 40 and 60% saturation of ammonium 
sulphate was dialyzed against 50 mM sodium 
phosphate buffer pH 7.5. This was subsequently 
chromatographed on Sephacryl-300 (82x1.5) in the 
same buffer. The fraction containing inhibitory 
activity against papain were pooled and concen-
trated. The purified protein gave single band on 4.5% 
native polyacrylamide gel electrophoresis (PAGE) 
and 4.5% SDS-PAGE. Molecular weight of HMWK 
estimated by SDS-PAGE was280kd. 
H M W K Antiproteolytic Activity 
The inhibitory activity of HMWK against papain was 
monitored by the method described by Kunitz.'^^' 
S D S Polyacrylamide Gel Electrophoresis 
HMWK (500 nmoles) treated with increasing 
concentration of riboflavin and different time 
intervals of incubation with riboflavin were 
examined by SDS-PAGE using 4.5% gel essentially 
as ouflined by Laemmli'^^' using tris-glycine buffer 
pH 8.3. Different scavengers and antioxidants 
were used in the incubation mixture of HMWK 
and riboflavin. 
Fluorescence Measurements 
Fluorescence measurements were performed with 
Hitachi F-2000 spectrofluorimeter with a 10 nm 
bandwidth for emission. The emission spectra of 
the inhibitor at 25°C in the region 300-400nm were 
recorded (protein concentration 500-600 nmoles) 
after exciting at 280nm.'""*' Tryptophan oxidation of 
protein incubated with riboflavin was monitored by 
loss of fluorescence peaks. Fluorescence emission 
spectra of HMWK incubated with riboflavin in 
presence of sodium azide, potassium iodide, 
thiourea, mannitol, ascorbic acid and uric acid were 
taken to determine the protective effects on 
tryptophan residues. 
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